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ABSTRACT
Cystic fibrosis (CF) is the most common, autosomal recessive lethal genetic
disease in the Caucasian population, resulting from a malfunctioned cystic fibrosis
transmembrane conductance regulator (CFTR) and leading to bacterial lung infections.
P. aeruginosa, an opportunistic pathogen, establishes a chronic infection in CF with a
phenotype of overproduction of an exopolysaccharide (alginate) due to host-directed
mutagenesis. While free-floating planktonic bacteria can be properly cleared from the
CF lung, P. aeruginosa, along with alginate production, establishes an infection in the
form of a biofilm which supports its survival in nature and in vivo. As a result, genomic
structure, gene and protein expression and pathogenicity vary from strain to strain,
potentially leading to differential roles in the CF lung. Unrelated phenotypic differences
in biofilm formation and lung colonization as well as variations in genome size, all within
different sources of P. aeruginosa were discovered and could lead to variations in
morbidity and mortality related to P. aeruginosa infections in CF. A key factor in
alginate regulation is AlgU/AlgT, a sigma factor that also impacts the expression of many
other involved proteins. One such protein, AlgB, is a response regulator of a twocomponent system together with KinB, responsible for regulating the expression of algD,
involved in alginate biosynthesis, through algU.

AlgB, when nonphosphorylated,

interacts through algU to synthesize alginate. Additional alginate loci were located
within the P. aeruginosa PAO1 genome utilizing isogenic mucoid mutants coupled with
PAO1-derived cosmid complementation. Another factor, MucD, was further classified in
its role in alginate suppression and temperature sensitivity. P. aeruginosa small colony
variants (SCVs) which prefer the biofilm mode of growth, thrive in harsh environmental

conditions and are found in the chronically infected CF lung, were generated in the
laboratory for further study. Addtionally, alginate alone was enough to modify the ability
to colonize a susceptible mouse lung, resulting in varied mortality and virulence. Finally,
novel genetic tools were fashioned for genomic mutagenesis and rapid gene knockouts.
Taken together, the phenotypic and genotypic analysis of the regulation of alginate may
further lead to treatments to prevent biofilm formation and subsequent CF host
colonization with P. aeruginosa.
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CHAPTER 1. GENERAL INTRODUCTION
INTRODUCTION
Pseudomonas aeruginosa is a ubiquitous bacterium found in the environment and
clinically. The genotypic and phenotypic diversity of this organism allows its survival
within almost any habitat. Recently, much focus in clinical microbiology has been
placed on the formation of biofilms.

Biofilms are defined as microcolonies of

microorganisms surrounded by an exopolysaccharide matrix, growing together on a
surface. From catheters to heart valves, the biofilm phenotype is a clinically relevant
phenotype assumed by bacteria in order to escape environmental stresses and thrive.
In cystic fibrosis (CF), P. aeruginosa establishes a biofilm within the lung of the
susceptible patient, coupled with overproduction of the exopolysaccharide alginate. This
polysaccharide is the matrix responsible for growth and maturity of the biofilm, and the
related protective mechanisms against environmental stresses. In CF, many approaches
are taken to combat lung infections including enzymatic treatments to break up the thick
mucous, inhaled antibiotics and percussive therapy. On the bacterial side, steps can also
be taken to improve the clinical prognosis of the CF patient. While some attention has
been placed on understanding the formation of P. aeruginosa biofilms and alginate
production, there is much more information left to be uncovered.
The focus of this study was to further elucidate the mechanisms involved with the
formation of P. aeruginosa biofilms in the CF lung. Much of the genomic information
regarding the regulation of alginate production has yet to be discovered. The studies that
follow focus on understanding the phenotypic diversity of P. aeruginosa, identification
and classification of new alginate genes as well as novel tools to perform the current and
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future studies.

Also, focus is placed on further understanding the currently known

alginate regulators as well as how alginate affects the P. aeruginosa-infected lung. With
further understanding of the regulation and biosynthesis of alginate, the key component
of biofilms, then more directed treatments can be utilized to target this detrimental
phenotype in the CF lung.
LITERATURE REVIEW
Cystic Fibrosis
Cystic fibrosis (CF) is a chronic, progressive and mostly fatal genetic disease. It
affects approximately 30,000 primarily Caucasian children and adults in the United
States. One in 31 Americans is an unknowing, asymptomatic carrier of the mutant CF
gene. The disease occurs in about 1 in every 3,200 live Caucasian births in the United
States, with approximately 30,000 living with CF. Currently, the median age of survival
for CF patients is 35.1 years and most are diagnosed before the age of 3.
CF arises due to mutation in the cystic fibrosis transmembrane conductance
regulator or CFTR gene (21). There are currently over 1,400 different types of CFTR
mutations resulting in CF. The most common mutation, accounting for over 70% of all
CFTR mutations, is a three base pair deletion resulting in the removal of a phenylalanine
residue at position 508 (ΔF508). The consequence of this mutation is retention of the
mutant CFTR protein within the endoplasmic reticulum, unable to be exported to the cell
membrane (14). CFTR is an anion channel regulator located on the apical plasma
membrane (137). This multifunctional protein controls the flow of Na+, Cl- and other
ions across the membrane.

Defects associated with CFTR mutations involve many

clinical problems but center around organ systems rich in exocrine glands such as the
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gastrointestinal, genitourinary and respiratory tracts (129). About 85% of CF patients are
diagnosed with pancreatic insufficiency (PI) due to malnutrition and decreased fat
absorption and are treated with water-miscible forms of fat-soluble vitamins A, D, E and
K (99). Approximately 10-15% of patients have a condition known as meconium ileus
(MI), an intestinal blockage due to malabsorption (134). More than 95% of males with
CF are infertile due to azoospermia resulting from absent, atrophic or fibrotic Wolffian
duct structures.
In the respiratory tract, the major clinical focus in CF, an electrolyte imbalance,
leads to physiological changes in the normal airway surface liquid (ASL) that lines the
upper and lower respiratory tracts. These changes in the ASL include variations in the
pH as well as reduced water content, resulting in a dehydrated, viscous mucous within the
lung. This abnormal mucous leaves the lung deficient in clearance of environmental
contaminants, including microbial organisms (28).
CF patients acquire a unique collection of bacterial pathogens, normally in an
age-dependent sequence.

Early infections often begin with Staphylococcus aureus,

followed by Haemophilus influenzae, both normally within the CF patient’s first year.
Both these infections can be removed by way of conventional antimicrobial therapy, yet
they continue to reemerge throughout the life of the CF patient.

Pseudomonas

aerugniosa becomes the most significant pathogen in the CF lung, establishing a
permanent residence beginning from the mean age of 15 months. Other organisms may
inhabit the CF lung, including the pathogenic Burkholderia cepacia; however, P.
aeruginosa ultimately leads to the demise of the patient due to respiratory failure. The
physiological manifestation of CF is very well understood; however, the link between
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this disease and the lung colonization by P. aeruginosa has not explicitly been
determined.
P. aeruginosa
P. aeruginosa is a motile, Gram-negative environmental bacterium that is
ubiquitous in nature. This organism can be found in soil, rivers, space vehicles as well as
colonizing humans, invertebrates, insects and plants.

P. aeruginosa is also an

opportunistic pathogen for individuals with compromised immune systems, including
wound infections in burn patients as well as a chronic pneumonia in CF (136).
The genome of P. aeruginosa has been completely sequenced and annotated
(126). The P. aeruginosa standard strain PAO1, originally isolated from a burn wound,
contains 6,264,403 base pairs and has a G+C content of 66.6%. P. aeruginosa has the
largest genome of the sequenced pathogenic bacteria and encodes 5,570 open reading
frames (ORFs) (Table 1). The genetic complexity of this bacterium is reflected in the
number of two-component systems (144 versus 62 in Escherichia coli), responsible for
gene regulation through an environmental response. P. aeruginosa also has a larger
number of efflux pumps than E. coli, showing its inherent drug resistance. Many P.
aeruginosa ORFs have yet to be characterized (approximately 70%); therefore, there is
still much to be discovered with this bacterium.
Alginate Production
P. aeruginosa isolates from the CF lungs are very distinctive from those that
cause other types of infections, as well as those found throughout the environment. This
unique in vivo environment is the only situation where P. aeruginosa is converted to the
alginate overproduction phenotype (mucoid). Alginate is a polysaccharide, consisting of
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Table 1. Completed genomes from a representative group of pathogenic bacteria1 (146)
Organism
Genome size ORF #
Accession #
Release date
H. influenzae Rd
1,830,138
1,709
NC_000907
07/25/95
E. coli MG1655
4,639,221
4,289
NC_000913
10/13/98
4,411,529
3,918
NC_000962
6/11/98
Mycobacterium tuberculosis
H37Rv
Vibrio cholera O1 El Tor
4,033,464
2,736
NC_002505
6/14/00
1,092
NC_002506
P. aeruginosa PAO1
6,264,403
5,5702
NC_002516
5/16/00
E. coli O157:H7
5,529,376
5,283
NC_002655
1/25/01
3,268,203
2,720
NC_002677
2/20/01
M. leprae
1
based on www.ncbi.nlm.nih.gov/PMGifs/Genomes/bact.html
2
based on www.pseudomonas.com
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a polyuronic acid, which is exported outside of the cell in the form of a capsule (Figure
1). This phenotype manifests in genetic mutations to the bacterium while residing within
the CF lung (78). In vitro studies have shown that sublethal concentrations of hydrogen
peroxide, a product of polymorphonuclear neutrophils, can cause this conversion from
non-mucoid to mucoid (79).
The overproduction of alginate is an essential process by P. aeruginosa regarding
its survival in the CF lung (Figure 2). Alginate is produced by the proteins encoded by
the alginate biosynthetic operon, consisting of 12 genes, beginning with algD (Figure 3,
(16)). These genes are responsible for the creation of the sugars, placement in the correct
orientation, assembly of the polysaccharide, as well as the machinery used to export the
polysaccharide outside the bacterium. One of the main factors involved in up-regulation
of algD expression, AlgU/AlgT, is an alternative sigma factor and is the key regulator of
alginate production (148). AlgU is referenced to as an “alternative” sigma factor as an
alternative to primary housekeeping sigma factors.

AlgU interacts with the core

polymerase to form the holoenzyme and drive algD synthesis. Mutations in algU are the
most common cause of mucoid conversion of P. aeruginosa in CF patients. AlgU autoregulates its expression from two promoters and is negatively regulated by the immediate
downstream cluster mucABCD, where MucA is the cognate anti-sigma factor for AlgU
(148). MucA is an inner membrane protein with its C-terminus proposed to interact with
MucB, and its N-terminus interacting with AlgU. Inactivation of MucA, MucB and
MucD causes conversion to mucoidy. MucD, a DegP (HtrA) homolog, is a periplasmic
serine protease that degrades improperly folded or damaged proteins. The homolog of
AlgU in E. coli is RpoE, which has been shown to functionally complement the algU
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Figure 1.

A mucoid phenotype expressed by P. aeruginosa due to the excessive

production of alginate (146).

Alginate helps to maintain the three dimensional

architecture of mature biofilms known to be resistant to host defenses and antibiotics.
Shown is a mucoid colony morphology from a clinical CF isolate of P. aeruginosa
growing on Pseudomonas Isolation Agar (PIA).
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Figure 2. Transmission electron micrograph (TEM) of a thin-section of postmortem lung
sample from a CF patient (64). Shown is P. aeruginosa in a mature biofilm, a persistent
infection phenotype closely associated with chronic bacterial lung infections in CF. P.
aeruginosa is embedded within a mucous matrix produced by bacteria and host. B –
Bacteria; S – Slime (alginate)

8

9

mutation and restore alginate overproduction in P. aeruginosa (149). Another alternative
sigma factor, RpoN, has been shown to be responsible for alginate production in PAO579
(muc-23), an isogenic mutant of P. aeruginosa PAO1 (10). Additional factors that
positively affect algD expression include AlgB and AlgR, response regulators of separate
two-component signal transduction systems. The alginate phenotype, besides being a
protective mechanism for individual P. aeruginosa bacteria, is also essential in the
assembly of P. aeruginosa into mature structures known as biofilms, in order to further
sustain their viability.
Biofilm Formation
Many stressful environmental factors have driven microbial populations to
develop various mechanisms to counteract such stresses in order to survive. One major
phenotypic change in bacterial communities is the formation of biofilms, defined as
microcolonies surrounded by an exopolysaccharide matrix, growing on biotic or abiotic
surfaces (103). In natural environments, such as rivers, biofilm growth is the preferred
form of growth, as it exceeds free-floating cell growth by 2-4 log10 units (23). In the CF
lung, the stresses facing P. aeruginosa survival direct it towards the biofilm phenotype.
The formation of biofilms is driven by not only the direct interaction of P. aeruginosa
with a surface, but the availability of a matrix, alginate, in which to develop the mature
formation.
Biofilms establish into larger formations through roughly four phases: i) initial
attachment of cells to a surface; ii) cell proliferation forming a monolayer; iii) formation
of a microcolony with the aid of a supportive matrix; iv) development into larger, mature
biofilm structures. Biofilms have the ability to form in common locations such as a
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flowing stream, or uncommon locations such as outer space. In space travel, vehicle
compartments are plagued by great temperature variations, producing water
condensation, thereby allowing optimal growing conditions for large bacterial biofilms
within spacecraft and stations. The biofilms formed may even occlude the ability to see
out of viewing windows in space. Mature biofilms surrounded by an exopolysaccharide
coat can fragment off where individuals inhale, often leading to a multi-focal low-grade
pulmonary infection due to the inability of the immune system to engulf this large mass
of bacterial growth. The same number of independently separated (planktonic) bacteria
could be effectively removed, and the individual would not develop a lung infection (25).
The process of biofilm formation is also important clinically. In the CF lung, this
process is not fully understood; however, many in vitro studies have outlined key factors
responsible for the methodical formation of P. aeruginosa biofilms. First, the initial
phase of attachment to a surface seems to be motility-mediated, in that P. aeruginosa
overcomes the surface repulsion forces for bacteria and comes into contact with a surface
most likely when propelled by its own method of movement (Figure 4; (46, 89, 125)).
The presence of type-IV pili also allows the further development of the thin monolayer
(89). The twitching activity of these pili may not necessarily be the reason for further
biofilm development, because hyperpiliated P. aeruginosa with no twitching ability are
still able to ultimately form thick, mature biofilms (31).

Other surface-associated

proteins are thought to be involved in early biofilm formation including curli as well as a
new chaperone/usher pathway involved in novel adhesin assembly (133).
After the formation of the monolayer, further biofilm development also requires a
cell-density dependent communication ability known as quorum sensing, consisting of
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Figure 4.

A hypothetical process of P. aeruginosa colonization leading to biofilm

formation in CF (146). Flagella-mediated motility is involved in the initial attachment.
Type-IV pili and a quorum sensing signal (3OC12-HSL) participate in microcolony
differentiation. Overproduction of alginate, which results in the formation of mature
biofilms, can be caused by mucA mutations induced through stresses such as oxidants
released by PMNs. The level of C4-HSL is increased in mature biofilms. Sessile cells
can be sloughed off as planktonic cells due to mechanical factors (ex. coughing).
Biofilms may be different from each other physiologically because of differences in
motility-, quorum sensing- and overproduction of alginate-mediated activity.
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two systems, las and rhl (98). These two systems act together to coordinate requires a
cell-density dependent communication ability known as quorum sensing, consisting of
two systems, las and rhl (98).

These two systems act together to coordinate P.

aeruginosa gene expression relevant to survival in the biofilm phenotype.

N-(3-

oxododecanoyl)-L-homoserine lactone (3OC12-HSL) and N-butyryl-L-HSL (C4-HSL) are
known to be involved in cell-to-cell communication (96, 97). 3OC12-HSL has been
shown to be involved in microcolony differentiation (27). A recent study reported levels
of C4-HSL were higher than 3OC12-HSL when analyzed in CF sputum carrying P.
aeruginosa (119). This suggests that C4-HSL may be important in later stages of biofilm
formation. Alginate does not seem to be required for initial biofilm formation (31, 86).
Also, wild-type PAO1 and PAO1 lasI

-

both produced equal amounts of alginate,

supporting the notion that alginate production is independent of at least 3OC12-HSLmediated quorum sensing (27).
Overall, the combination of P. aeruginosa alginate overproduction and biofilm
formation in the CF lung prolongs bacterial existence and colonization.

While

conventional antimicrobial therapy is effective in removing early bacterial colonists, the
protective phenotypes assumed by P. aeruginosa aid in the evasion from external
stresses. Multiple studies have shown that antibiotic treatment of P. aeruginosa biofilms
are much less effective compared to treatment of equal bacterial counts of free-floating
planktonic cells (24).

Concurrently, the immunological response from the CF host

includes PMNs. Due to the depth of bacteria within a biofilm, these immune cells find it
difficult to effectively remove the large mass of microorganisms. Even coupled with the
response of phagocytic macrophages, the mere size of a grouping of bacteria surrounded
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by alginate proves difficult to ingest, leading to a phenomena known as “frustrated
phagocytosis.” Ultimately, this continued immunologic assault on the colonized CF lung
leads to further lung deterioration and subsequent respiratory failure and death (53).
Genetic Diversity
P. aeruginosa isolates from clinical environments, CF patients and the
environment all display a high level of genomic polymorphism. This is also referred to
as genomic diversity (59, 108, 110).

This genetic diversity, from an evolutionary

perspective, enhances the phenotypic diversity of the organism.

To visualize such

variability in genomic structure, one can perform macrorestriction digestion of the
chromosome coupled with physical separation of DNA fragments in a pulsed-field gel
electrophoresis (PFGE) system (Figure 5; (109)). The resulting banding pattern is fairly
distinct to individual samples and is referred to as a restriction fragment length
polymorphism (RFLP) profile. Another method used to identify the genomic variability
between isolates of P. aeruginosa is random amplification of polymorphic DNA (RAPD)
and is a PCR-based technique employing random primers and a low annealing
temperature (75, 105). This technique gives a characteristic PCR amplification banding
profile that can be unique for each individual isolate.
The ultimate cause of genomic diversity in P. aeruginosa clinical CF isolates is
mutation (135). One type of genetic manipulation involves the acquisition of auxiliary
DNA from within or between species or even genera (44). There is much evidence
present to suggest that horizontal gene transfer occurs in P. aeruginosa (5, 68, 135). An
early study was among the first to discover that the genome size of a clinical CF isolate
of P. aeruginosa was significantly larger than that of PAO1 (116). Subsequently, a
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Figure 5. Separation of SpeI-digested P. aeruginosa chromosomal DNA by PFGE (146).
(A). CF006 and CF007, two clinical CF isolates, display the genomic diversity that exists
throughout the majority of clinical isolates. Environmental strains (ENV42: Japan, and
PAOH: Ohio River) of P. aeruginosa also exhibit a diverse chromosome. (L - size
standard ladder) (B). Burn isolates PAO1 and PA14 also possess diversity along the
chromosome.

Clinical sequential isolation of P. aeruginosa shows conservation of

genome throughout colonization (CF041: initial isolate in 1990, CF042: isolated in 1994,
CF043: isolated in 1998).

15

clinical wound isolate of P. aeruginosa, PA14, was shown to have several unique
chromosomal regions not present in the PAO1 genome (73, 127). A recent study has
identified the first genomic island in a clinical isolate of P. aeruginosa (68). This
genomic island is absent in PAO1 but is present in 85% of the clinical isolates, including
some from CF patients (68). The island has a characteristic 49.2% G+C content versus
66.6% overall in PAO1, and measures over 48 kb in length (68).
Acquisition of this type of auxiliary DNA will definitely manifest in the
variability seen in RFLP and RAPD genomic patterns. There are potentially many more
islands of this type throughout other clinical and environmental P. aeruginosa isolates.
This addition of DNA could very well be a mechanism to diversify the bacterial
pathogenesis of these strains. As noted in a previous study, the virulent E. coli O157:H7
genomic sequence has an additional 1.34 megabases of DNA when compared with E. coli
K12, the laboratory standard strain (100). This additional DNA corresponded to 1,387
new genes in 177 O157:H7-specific genomic islands interspersed within a K12 genome
(100). It is possible that the similar acquisition of these mobile genetic elements by P.
aeruginosa could enhance its virulence, thereby allowing it to perform differently in
clinical situations, including the CF lung, from what is expected in highly studied
laboratory strains.

Aside from pathogenic enhancement, even simple phenotypic

characteristics could vary from strain to strain due to the variability of genomic material.
Aerosol Infection Mouse Model
To simulate a P. aeruginosa infection in CF, an appropriate animal model is
essential. CFTR transgenic mice are currently available and many studies have involved
these mice as models for CF (19, 20, 34, 87, 121, 131, 150). However, these mice do not
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fully mimic the human CF airway, in that alternative Na+ and Cl- channels in mice aid in
correcting the CFTR defect (17). While these methods exist to circumvent the CF defect,
it has been shown that the salt composition of the ASL in these mice is similar to human
ASL (26).

Also, colonization of the CF mouse lung is non-existent, however is

anticipated and found in CF children (57).
Numerous models of P. aeruginosa delivery are available and many center on two
distinct systems of inoculation (28, 143).

One involves artificially embedding P.

aeruginosa in small agar beads with subsequent tracheal instillation by surgical
technique. This model attempts to artificially simulate a biofilm, similar to a mature
biofilm infection. Another model focuses on inoculating with single cells by way of
aerosol infection.

This approach focuses on modeling the innate host response

immediately after initial P. aeruginosa colonization (11, 145, 147). This model is the
bacterial aerosol induced lung infection (BAILI) mouse model, which centers around
technology originally developed for tuberculosis studies (94). The core of this system is
an inhalation exposure system where artificially generated aerosols of P. aeruginosa are
evenly introduced into mouse lungs within the system (Figures 6, 7; (134)). The aerosol
is created using high-pressure nebulization and subsequent controlled negative pressure
to draw the aerosol through the exposure chamber at an even rate (28). To perform
studies using this system, a suspension of bacteria is loaded into a glass apparatus called
the nebulizer-Venturi unit. Within the loading area, a small hollow tube descends down
into the suspension. For nebulization, high-flow HEPA-filtered air is passed over the top
of this tube, drawing the suspension up the tube and propelling the flow directly at a
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Figure 6. The core of the Bacterial Aerosol Induced Lung Infection (BAILI) mouse
model: An inhalation exposure system (146). The BAILI mouse model is a wholebody aerosol-based infection model where artificially generated P. aeruginosa
aerosols can be evenly introduced to the murine lungs within the chamber, thereby
causing a lung-specific infection and inflammation in mice. The chamber holds up to
100 mice within 5 separate compartments and can be used as an efficient highthroughput screening device for monitoring pulmonary clearance and inflammatory
responses from the host.
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Figure 7.

Schematic diagram of the aerosol inhalation machine system (146).

Utilizing a negatively-pressured system powered by a vacuum pump at the end of the
arrangement, room air is passed through a HEPA filter #1 before entering the system.
A compressor produces the air pressure needed to aerosolize the bacterial suspension,
as shown in the inset. A valve controls the flow of the compressed air, regulating the
level of aerosolization. The main air is responsible for carrying the aerosol from the
nebulizer-Venturi unit to the inhalation chamber. Exhaust air with bacteria is filtered
(HEPA filter #2) and incinerated. UV lamps destroy residual bacteria within the
chamber as well as on the animal coats.
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suspended glass bead. This glass bead deflector aids in the dispersal of the aerosol. At
the end of the system, a vacuum exerts negative pressure on the flow of air in the
chamber. With the vacuum engaged, all nebulized suspension will be drawn through the
chamber at a pre-determined rate and through a HEPA filter and incinerator. Both the
compressed air and vacuum flow are manually controlled and can be changed based on
varying exposure variables. The main chamber consists of a round cage divided into 5
equal sections, capable of containing a total of 100 mice per cage. After the nebulization
and exposure, the aerosolization of the suspension is halted while the vacuum continues
to pull excess aerosol out of the system, otherwise known as “cloud decay”. Following
this cloud decay, UV lights on the underside of the door, above the cage are illuminated
to kill remaining bacteria that may have accumulated in high numbers on the animal coats
and on the cage. This system allows the initial colonization of mice with a precise
delivery of inoculum and further analysis of the first immune response.
This dissertation will focus on P. aeruginosa biofilms and the identification and
classification of factors involved in biofilm formation and biofilm survival related to CF
lung infections. The following six chapters will address this approach through multiple
aspects. In chapter 2, genotypic and phenotypic variations among differing sources of P.
aeruginosa are shown to not be related to biofilm formation. In chapter 3, a twocomponent system involved in P. aeruginosa alginate regulation is shown to have a dualrole. One role up-regulates type-IV pili synthesis and another up-regulates alginate
synthesis, each based on the phosphorylation state of the response regulator in the
system. In chapter 4, novel biofilm regulators are identified by utilizing genetic info
from the P. aeruginosa PAO1 genome. Also, a known alginate suppressor, MucD, is
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further investigated as to the role of the functional domains. In chapter 5, a clinically
relevant biofilm forming phenotype, the small colony variant, is found to emerge not only
from the CF lung but also from the laboratory. In chapter 6, the production of alginate by
clinical CF isolates is found to suppress the immune respone and subsequent morbidity
and mortality in a susceptible mouse model. This apparent suppression in virulence with
the CF isolate differs compared to a more virulent, alginate-producing PAO1 mucoid
mutant, leading to increased mortality. In chapter 7, new genetic tools are created to
further determine the factors involved in the regulation of biofilm formation. These tools
combat increasing concerns with antibiotic resistance of P. aeruginosa strains and timely
inactivation of genes of interest. Through these studies, a more comprehensive approach
can be taken to identify and classify biofilm formation factors of P. aeruginosa and their
related effect in the CF lung.
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This chapter focuses on the diversity that exists between differing sources of P.
aeruginosa (49). Isolates from the environment, from non-CF clinical situations, from
CF patients and from the laboratory were compared side-by-side to determine the extent
of diversity within this species. Initial biofilm formation was measured in vitro and was
found to vary greatly between strains. When comparing initial biofilm formation versus
flagella, type-IV pili and alginate production, these phenotypic characteristics varied
greatly within themselves, but no correlation existed with the amount of biofilm formed.
The CF isolates of P. aeruginosa seemed to grow more efficiently under biofilm
conditions as opposed to planktonic growth. Hydrogen peroxide treatment of planktonic
CF isolate growth was deemed more effective than treatment of biofilm growth. Also,
CF isolates showed reduced lung colonization in an aerosol lung infection mouse model
when compared to non-CF isolates.

While RFLP profiles of P. aeruginosa strains

showed the extent of diversity, additional DNA is implicated in many clinical isolates,
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including some previously identified genomic islands. Using RAPD and subtractive
hybridization, some of these novel sequences were identified.
ABSTRACT
Chronic lung infections with Pseudomonas aeruginosa biofilms are associated
with refractory and fatal pneumonia in cystic fibrosis (CF). In this study, a group of
genomically diverse P. aeruginosa isolates were compared with the reference strain
PAO1 to assess the role of motility, twitching, growth rate and overproduction of a
capsular polysaccharide (alginate) in biofilm formation. In an in vitro biofilm assay
system, P. aeruginosa displayed strain-specific biofilm formation that was not solely
dependent on these parameters. Compared with non-CF, CF isolates expressed two
opposing growth modes: reduced planktonic growth versus efficient biofilm formation.
Planktonic cells of CF isolates showed elevated sensitivity to hydrogen peroxide, a
reactive oxygen intermediate and decreased lung colonization in an aerosol infection
mouse model. Despite having identical genomic profiles, CF sequential isolates produced
differing amounts of biofilm. While P. aeruginosa isolates exhibited genomic diversity,
genome size of these isolates was estimated to be 0.4 to 19% (27 to 1,184 kb) larger than
that of PAO1. To identify these extra genetic materials, random amplification of
polymorphic DNA (RAPD) was coupled with PAO1-subtractive hybridization. Three loci
were found within the genomes of two CF isolates encoding one novel homolog involved
in retaining a Shigella virulence plasmid (mvpTA) and two divergent genes that function
in removing negative supercoiling (topA) and biosynthesis of pyoverdine (PA2402).
Together, P. aeruginosa biodiversity could provide one cause for the variation of
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morbidity and mortality in CF. P. aeruginosa may possess undefined biofilm adhesin(s)
that are important to the development of an anti-biofilm therapeutic target.
INTRODUCTION
P. aeruginosa, a gram-negative environmental bacterium is responsible for the
majority of morbidity and mortality in CF (71). Lung infections with this bacterium
manifest in varying disease severity. Particularly, in CF chronic lung infections, P.
aeruginosa develops a characteristic phenotype, surrounded by an overproduced capsular
polysaccharide called alginate (43), and associated into large bacterial conglomerates
known as biofilms (22). It is this formation that allows the bacteria to survive within the
CF lung and elicit unproductive immune responses that ultimately result in the demise of
the patient (53).
Biofilms are formed from individual free floating (planktonic) cells and are
defined as alginate-surrounded bacteria, or microcolonies, growing on biotic or abiotic
surfaces (102). Biofilms are ubiquitous in nature and are also associated with numerous
chronic or recurrent bacterial infections and diseases (33). Formation of biofilms by this
bacterium can be viewed as a developmental process (88) that is roughly divided into
four steps: (i) adhesion, (ii) monolayer, (iii) microcolony, and (iv) mature biofilms (24).
In recent years, considerable progress has been made with regard to the molecular
components that promote biofilm formation. Several surface-associated factors such as
flagella and type-IV pili have been shown to be essential for adhesion and microcolony
formation respectively (90, 125) as well as other undefined adhesins (32, 95, 130, 132).
Flagella act to overcome repulsive forces between the bacterium and surface to allow the
initial contact (102). Following adhesion of single bacteria into the formation of a
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monolayer, twitching motility is used to initiate the grouping of cells into microcolonies
(90). Further development of biofilms leads to the emergence of mature biofilms, which
are characterized by alginate-encased bacterial aggregates (43).
The genome of the reference strain P. aeruginosa PAO1 is available (126).
However, the functions of the majority of the genes within this genome remain elusive.
Furthermore, P. aeruginosa isolates are known to possess extensive genome diversity
(107), of which the origin is yet to be completely defined. There are, however, many
isolates that carry additional genetic materials that are missing in PAO1 (65, 123). Two
such examples include the identification of P. aeruginosa genomic islands 1 (67) and 2
(5) (PAGI-1 and -2). While the functions of PAGI-1 are proposed to play a role in
immune evasion (67), PAGI-2 is involved in glycosylation of the flagellin protein, a
function that is not present in PAO1 (5). Therefore, genomic diversity may allow this
bacterium to expand its pathogenic potentials.
While CF isolates are known to have the ability to attach to a surface and form
biofilms (118), it is not clear whether there is an intrinsic difference in biofilm formation
among genomically diverse environmental and clinical isolates of P. aeruginosa. In this
report we will examine the role of four biofilm-related factors in biofilm formation:
motility, twitching, growth rate and overproduction of alginate. Our studies have shown
that while flagellar and type-IV pili activities are required for the initiation of biofilm
formation, they play no quantitative role in the progressive development of the initial
biofilm microcolony. Also, we demonstrate increased H2O2 sensitivity and decreased lung
colonization in an aerosol infection mouse model with CF isolates relative to non-CF.
Two opposing modes of growth are indicative of CF isolates: efficient biofilm formation
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and reduced planktonic growth rate. The genomic diversity found throughout many P.
aeruginosa isolates appears to be due considerably to the presence of large portions of
DNA not found in PAO1. We also examined the cause of genomic diversity as a function
of novel DNA inclusion. RAPD coupled with subtractive hybridization was used to
identify genes novel to or existing in a highly varying form in PAO1. Our results lead us
to conclude that CF isolates of P. aeruginosa differ greatly in many aspects of biofilm
formation among each other and also when compared with non-CF.
MATERIALS AND METHODS
Bacterial strains. Strains used in this study are listed in Table 2. P. aeruginosa and E.
coli strains were grown at 37°C in Lennox broth (LB), on LB agar or Pseudomonas
Isolation Agar (PIA) plates unless otherwise noted. For the flagellar activity assay, P.
aeruginosa was grown on motility test medium (MTM, Becton Dickinson).
Biofilm assay. The assay for biofilm formation was adapted from the procedure as
previously described (91). Briefly, P. aeruginosa overnight culture was diluted 1:100 in
fresh LB medium, dispensed (125 μl) to wells of a 96-well polyvinyl chloride (PVC)
microtitre plate and grown for 15 h at 37°C (unless otherwise noted) with no aeration.
Wells were stained with 100 μl 0.5 % crystal violet (CV) for 30 min at room temperature.
Stain was discarded, plate was rinsed 3-5 times in standing water and allowed to dry.
Stained biofilm was solubilized with 200 μl 95% ethanol for 10 min and read at optical
density at 570 nm (O.D.570). For light microscopy, biofilm samples were removed from
the stained biofilm assay 96-well microtitre plates with a razor blade and wet-mounted on
a specimen slide. Samples were viewed under normal light microscopy.
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Table 2. Phenotypic characteristics of P. aeruginosa isolates
Isolate1
CFS1
CFS2
CFS3
CFS4
CF001
CF005
CF017
CF040
CF049
CF5
CF15
CF25
CF29
CF37
CF46
CF149
104035
114199
203084
203097
226281
311058
822026
ERC-1
ENV42
OR
PAO1
CF032
CF9
CF011
CF029
PA14

Biofilm2
3.1
4.7
1.6
4.6
4.0
5.5
5.5
4.6
3.2
2.2
3.9
2.2
1.7
3.2
1.8
3.8
1.3
2.9
3.5
6.6
6.0
1.8
2.9
3.8
2.2
2.8
1.0
0.6
0.1
-

Motility3
0.8
0.3
0.3
0.6
0.2
0.3
0.1
0.8
0.5
0.3
0.4
0.4
0.1
0.3
0.8
0.7
0.9
0.6
0.5
0.6
0.6
0.9
0.9
0.9
0.6
0.3
1.0
0.6
0.3
0.1
0.0
0.8

TFP4
23
11
29
9
7
22
31
22
11
15
25
25
19
30
22
16
26
16
26
P

DT5
1.3
1.9
1.0
1.8
2.3
3.0
2.7
1.3
1.8
1.4
1.3
2.6
1.8
1.0
1.1
0.8
1.1
1.1
0.8
1.2
1.3
1.5
1.4
0.8
0.8
1.5
0.8
1.7
2.5
1.2
4.8
1.0

1

Mucoid6
1.2
0.9
0.5
1.5
0.5
1.7
2.4
2.0
1.0
0.8
0.8
4.0
5.5 (M)
5.0
1.5
1.2
1.8
2.1
1.0
1.0
0.6
1.9
3.4
0.8
2.3
1.7
1.7
0.6
0.6
1.9
0.8
0.7

Sources
CF-94
CF-97
CF-98
CF-98
CF
CF
CF
CF
CF
CF
CF
CF
CF
CF
CF
CF
Biopsy
Sputum
Sputum
Wound
Eye
Sputum
Blood
Env
Env
Env
Wound
CF
CF
CF
CF
Wound

References7
Speert
Speert
Speert
Speert
Speert
Speert
Hoiby
Phibbs
Speert
Govan
Govan
Govan
Govan
Govan
Govan
Pier
Guymon
Guymon
Guymon
Guymon
Guymon
Guymon
Guymon
Stoodley
Speert
Somerville
Phibbs
Hoiby
Govan
Hoiby
Hoiby
Ausubel

A group of 32 isolates was used in this study. Except for the sequential isolates (CFS1-S4), the genomic
profiles of these isolates were different when examined with the SpeI digestion of genomes and followed
by PFGE separation.
2
Shown is the relative fold increase of biofilm formation in comparison to PAO1. – notes that the level of
biofilm formation was much lower than the level of PAO1.
3
Motility is expressed as a relative ratio of the swimming zone between isolates and PAO1.
4
TFP (type-IV pili) mediated twitching activity was measured as described by Alm and Mattick (3). Shown
are the actual twitching zones in mm. – notes that measurement was below the detection limit.
5
DT (doubling time), the time (h) required to double the bacterial population in LB medium within the 96well plate at 37°C, was determined during the log phase of bacterial growth.
6
Alginate production was measured based on growth on LB plates at 37°C for 48 h. Mucoid measurement
was expressed as μg of uronic acid per mg wet cell mass. Mucoid (M) phenotype was determined after 48
h growth on LB agar at 37°C.
7
The P. aeruginosa isolates used in this study were obtained from the following individuals, Speert: Dr. D.
Speert, University of British Columbia, British Columbia, Canada; Hoiby: Dr. N. Hoiby, University of
Copenhagen, Copenhagen, Denmark; Phibbs, Dr. P. Phibbs, East Carolina University Pseudomonas
Genetic Stock Center, Greenville, SC; Govan: Dr. J. Govan, University of Edinburgh, Edinburgh, Scotland;
Pier, Dr. G. Pier, Harvard Medical School, Boston, MA; Guymon, Dr. C. Guymon, US Army Institute of
Surgical Research, Fort Sam Houston, TX; Stoodley, Dr. P. Stoodley, Montana State University, Bozeman,
MT; Somerville, Dr. C. Somerville, Marshall University, Huntington, WV; Ausubel, Dr. F. Ausubel,
Harvard Medical School, Boston, MA.
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Determination of motility and twitching activity. Equal concentrations of P.
aeruginosa isolates, as adjusted by O.D. (corresponding to CFU/ml) from an overnight
culture, were used to inoculate MTM or LB plates. An inoculation needle was placed in
the culture, and stabbed vertically into the media. Plates were incubated overnight at
37°C for the motility assay and the motility-mediated swimming zone was measured in
mm. After incubation, the agar was removed from the twitching activity plate and stained
with 0.25% Coomassie blue (wt/vol) for 30 min. Stain was removed and twitching
activity was measured in mm.
Determination of planktonic and biofilm growth rate. For static planktonic growth
rate, O.D.570 readings of biofilm assay plates were taken every 30 min starting t = 0 until
the density reached 0.07, at which readings were taken every 15 min for a total time of 15
h. For biofilm growth rate, duplicate 96-well plates were tested for biofilm formation at t
= 0, 1, 3, 4.5, 6, 8, 10 and 15 h. Furthermore, a shaken culture of 200 ml culture was
assayed every 30 min for a total time of 6.5 h. For determining the viable cell count from
biofilm, 96-well plates were tested for biofilm formation after 15 h. Duplicate plates were
washed gently with sterile water and the biofilm growth was removed by sterile swab,
plated and CFU/16 wells was determined. To calculate the specific growth rate for all
growth modes, the exponential growth phase was selected on a graph of ln O.D. versus
time (61). The specific growth rate was defined as the slope of the regression line (1/h).
H2O2 sensitivity assay. This assay was based on a previously published method (149)
except paper disks were impregnated with 10 μl 12% H2O2.
Catalase assay. P. aeruginosa cell suspensions in phosphate buffer (pH 7.4) were bead
beat for 60 s x 3 while on ice. The supernatant was measured for protein concentration
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using the DC Protein Assay (Bio-Rad). Catalase activity was determined by Catalase
Assay Kit (Cayman Chemical, Ann Arbor, MI).
Pulsed-field gel electrophoresis (PFGE). PFGE analysis of genomic profiles of P.
aeruginosa isolates was adapted from the standard enterobacteria procedure developed by
CDC (PulseNet, Section 5, Preparation of PFGE Plugs from agar cultures,
www.cdc.gov). Briefly, P. aeruginosa overnight culture (5 ml) was pelleted and
resuspended

in

1

ml

cell

suspension

buffer

[100

mM

Tris;

100

mM

ethylenediaminetetraacetic acid (EDTA), pH 8.0] to 10% transmittance as indicated by
the BioMerieux Vitek colorimeter. The cell suspension (200 μl) was combined with 200
μg proteinase K and inverted 6 times. A mixture of 1.6% InCert agarose (FMC
BioProducts, Rockland, ME) and 1% sodium dodecyl sulfate (SDS) [1.6% Incert/1%
SDS mixture: 0.8 g InCert agarose; 2.5 ml 20% SDS; 46.7 ml Tris-EDTA buffer (TE)]
(200 μl) was mixed with the cell suspension/proteinase K mixture and dispensed in an
agarose plug mold (Bio-Rad). After solidifying, the cells were lysed within the plug using
1.5 ml cell lysis buffer (50 mM Tris; 50 mM EDTA, pH 8.0; 1% N-Lauroylsarcosine)
and 800 μg proteinase K for 1.5 h in a 54°C water bath with agitation. Plugs were then
washed twice with 10 ml pre-heated, sterile, reagent grade H2O for 15 minutes and twice
with 10 ml pre-heated TE buffer for 15 min, with all washes performed in a 48°C water
bath with agitation. Portions of the plugs (1.5 mm) were digested with restriction enzyme
SpeI (20 U), DpnI (14 U), or XbaI (50 U) for 1 h at 37°C. Portions of the plugs (6 mm)
were equilibrated with reaction buffer for 3 h at 4°C and digested with I-Ceu I (0.8U) for
2 h at 37°C. Digested portions were loaded into an agarose gel of certain concentration
and subjected to certain separation conditions, both noted in the pertaining figure. The
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running buffer was 0.5X Tris-Borate EDTA (TBE). After PFGE, the gel was stained with
ethidium bromide (1 μg/ml) for 30 min and photographed under UV light.
Alginate assay. This assay was based on a previously published method (60) with the
following modifications. Isolates were inoculated onto LB plates and incubated for 48 h
at 37°C. Bacteria were scraped off the plates and suspended in 10 ml phosphate-buffered
saline (PBS; pH 7.4) and centrifuged at 3,000 rpm for 20 min. The supernatant was used
for the alginate assay.
RAPD. RAPD reactions were carried out with purified genomic DNA of P. aeruginosa
isolates using standard primers as previously described (74). The conditions that were
selected as the optimal conditions for obtaining accurate amplified band profiles with the
eight primers are as follows: assays were performed in 50 µl EasyStart PCR tubes
(Molecular BioProducts) with 2.5 U MasterAmp Taq DNA polymerase (Epicentre) and
0.5 µM of each primer. The temperature cycling that used a BioRad iCycler system was
as follows: 94°C for 4 min, 4 initial cycles consisting of 94°C for 2 min, 45°C for 5 min,
and 72°C for 5 min, followed by 30 cycles consisting of 94°C or 1 min, 45°C for 1 min,
and 72°C for 2 min and a final extension step consisting of 72°C for 10 min.
Southern hybridization. Agarose gels were soaked in 0.25 N HCl for 30 min, rinsed in
H2O, soaked in 1.5 M NaCl/0.5 M NaOH for 30 min and 1.5 M NaCl/0.5 M Tris-Cl, pH
8.0 for 30 min. A blotting apparatus was constructed with a filter paper wick, a HybondN+ membrane (Amersham Pharmacia Biotech) and transferred with 20X SSC transfer
buffer for 24 h. After transfer, the membrane was rinsed in transfer buffer and UV crosslinked. Hybridization and digoxygenin probe labeling were carried out as described by
the manufacturer (Roche Molecular Biochemicals). PAO1 DNA was fully digested with
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Sau3A, separated by electrophoresis on a 1% agarose gel and stained with ethidium
bromide. A particular section of the digested DNA gel corresponding to the size of 0.5-2
kb was removed, extracted using QIAquick gel extraction (Qiagen) by specifications of
the manufacturer, and used for labeling.
Transmission electron microscopy. P. aeruginosa overnight culture (2 ml) was
pelleted, washed with 500 μl PBS, pelleted and resuspended in 100 μl PBS. The cell
suspension (10 μl) and 2% phosphotungstic acid (PTA; 10 μl) were combined on a glass
slide. A Formvar-coated grid was placed on top of the mixture for 30 s. The grid was
allowed to dry overnight at room temperature. Grids were viewed using transmission
electron microscopy (Hitachi).
Examination of genomic islands by PCR. Amplification reactions of PAGI-1 and
PAGI-2 were carried out with purified genomic DNA using the following primers: PAGI1:

ORF18,

forward:

5’AATCGGTGCAAGGGAGTA;
reverse:

ORF22,

5’TGCCGAACACGATCAA;

5’TATCAGTGTCGGGCAAGA,
ORFA,

5’TAAGGGGTTCTAGCGGC,

forward:

5’AATGGTACATGGGGAAGT;

forward:

5’GACTTGCATGGGGCTT,

PAO1-specific

reverse:

(PA2221),

5’AGCTCCGGCAACCACTA;

5’TATGTTCCGCAAGGTCT,
PAO1-specific

reverse:

(PA1089),

forward:
PAGI-2:
reverse:
forward:

5’TGTGCGCACTGCCTAC, reverse: 5’GCAAGGTATTGGTTCGG. Assays were
performed in 50 µl EasyStart PCR tubes (Molecular BioProducts) with 2.5 U MasterAmp
Taq DNA polymerase (Epicentre) and 0.5 µM of each primer set. The temperature
cycling that used a BioRad iCycler system was as follows: 94°C for 1 min, 34 cycles
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consisting of 94°C for 1 min, 54°C for 2 min, and 72°C for 2 min, and a final extension
step consisting of 72°C for 8 min.
P. aeruginosa aerosol infection mouse model. P. aeruginosa overnight culture (1 ml)
was used to inoculate 100 ml LB broth and was grown for 14-16 h with aeration at 37°C.
The cells were pelleted and resuspended in 10 ml P-PBS (1% proteose peptone-PBS).
The cell suspension (5 ml) was dispensed into the nebulizer-Venturi unit of the Inhalation
Exposure System (Glas-Col, Terre Haute, IN) and aerosolized for 30 min (compressed air
control = 20; vacuum control = 50), cloud decayed for 25 min, and UV decontaminated
for 5 min. A total of 10 mice were exposed for each strain with 5 mice terminated at t = 0
and t = 6 h. Mice were sacrificed by carbon dioxide. The right lung was removed,
homogenized in 1 ml P-PBS and plated via serial dilution on LB agar.
DNA sequencing and bioinformatic analysis of novel genomic sequences. Purified
plasmids were sequenced using universal M13 forward and reverse primers. Sequencing
was performed using 11 μl (approximately 2 μg) purified plasmid, 1 μl (3.2 pmoles) of
unlabeled sequencing primer, and 8 μl Big Dye Terminator Reaction Mix (PE Applied
Biosystems). DNA sequencing was performed on an Applied Biosystems 310 Genetic
Analyzer (Foster City, CA)

at the Core Facility at Marshall University School of

Medicine. Once the DNA sequences were available, they were compared by BLAST to
GenBank and to the annotation of the PAO1 genome (www.pseudomonas.com).
RESULTS
P. aeruginosa isolates demonstrate differing ability of in vitro biofilm
formation. While P. aeruginosa strains possess complex, diversified genomes (59) and
readily form biofilms (22), it is unclear whether there are any variations in biofilm
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formation among clonally diverse clinical and environmental isolates of P. aeruginosa. A
total of 151 isolates (101 CF and 50 non-CF isolates) collected from geographically
diversified areas were first examined for their clonal relationship by macrorestriction
digestions of chromosomal DNA with SpeI, XbaI, and/or DpnI, followed by separation
using PFGE. The PFGE pattern of each isolate was compared with that of the reference
strain PAO1 (126) and also between these isolates. All PFGE patterns were unique except
for 16 sequential CF isolates, which is consistent with previous reports that CF
pulmonary infections are mainly associated with a predominant strain (13, 74, 106). Next,
all isolates were tested for biofilm-forming ability using an adaptation of a PVC 96-well
microtitre dish method (91). Since some CF isolates are auxotrophic and often require the
presence of several amino acids for growth in minimal media (6, 7), we chose to grow
these isolates in complex LB medium. The strain PAO1 was included as a standard in
every microtitre dish used to determine biofilm formation. A significant variation in
biofilm formation was found among all isolates tested (Figure 8A). To confirm that the
CV-stained samples at the air-liquid interface on the dish were true biofilm, a sample was
prepared and visualized microscopically, which was consistent with characteristics of
initial biofilms (Figure 8B). Furthermore, the majority of these isolates showed increased
amounts of biofilm than PAO1 (Figure 8A). A group of 32 phenotypically diverse
isolates were selected for further analysis. As shown in Table 2, biofilm formation of
these samples varied greatly in relation to PAO1. Only 5 of the samples (CF032, 9, 011,
029, and PA14) formed less biofilm than PAO1. Sequential isolates (CFS1-S4) (146)
from the same patient over a period of 4 years expressed differing levels of biofilm
formation. Furthermore, these isolates were also tested for biofilm formation in a 12-well
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Figure 8. A. Variations and (B) light microscopy of biofilm formation produced by
genomically diversified clinical and environmental isolates of P. aeruginosa in an in vitro
biofilm assay system. For each isolate within each 96-well plate in A, the assay was
repeated for a total of 8 times (vertically). Biofilm formation was analyzed along with
PAO1 (far right vertical lane of each plate). C. Relationship between CV-stained
materials (black bars) and biofilm viable counts (gray bars). D. Biofilm formation of
PAO1 and its derivatives and its relationship with alginate production.
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polystyrene plate, which was consistent with the PVC plate results. To test whether the
observed variations could be due to the relative hydrophobicity of these isolates, the
biofilm formation was also tested on a glass surface. The dynamic and trend of biofilm
formation on this surface was identical to that seen with PVC (data not shown),
suggesting that the relative hydrophobicity of these isolates is not involved in the
differences in biofilm formation. Since some isolates are from environment, biofilm
formation was compared between 30 and 37°C. No difference was seen among these
isolates (data not shown).
However, this variation, as observed with CV staining (Figure 8A), could be due
to the differing amounts of CV-absorbing extracellular materials. To test this, viable
counts of biofilms were measured and compared with the optical density of CV-stained
materials. Correlation was seen between biofilm CFUs and the optical density (Figure
8C), suggesting that the optical intensity is representative of the cell density in biofilms.
Furthermore, three isogenic strains, PAO1, PAO6862 (PAO1 algD::Gmr) (144) and
PAO578 (PAO1 mucA22), a hyper-mucoid strain known to maintain mucoid status on
LB plates (30) were assayed for the contribution of alginate on biofilm formation. When
stained by CV, PAO1 showed the highest amount of biofilm followed by PAO6862 and
the least biofilm producer, PAO578 (Figure 8D). These results are consistent with the
recent observation that alginate is probably not required for the initial phase of biofilm
formation (51, 141), and also conclude that CV staining is not indicative of the
extracellular matrix but the viable cells inside biofilms.
Flagellar- and type-IV pili-mediated activities are not proportional to biofilm
formation. The formation of biofilms is a multi-step process that requires participation of
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structural appendages such as flagella and type-IV pili (90). Variations in biofilm
formation, as seen in Figure 8, could be due to altered activities of these structural
appendages. To test this, we measured the motility and twitching abilities of the isolates
in Table 2. The flagellar activity of PAO1 was the greatest among all strains tested (Table
2, Figure 9A). However, PAO1 formed the least amount of biofilm compared to the other
6 CF isolates shown in Figure 9A. Furthermore, other isolates with increased motility
displayed elevated biofilm formation (CF040, ERC-1, Table 2). Thus, no quantitative
correlation was seen between the ability of the bacteria to assume a biofilm mode and
motility. In addition, when samples were negatively stained with 2% PTA and examined
using electron microscopy, all isolates showed the presence of flagella (data not shown).
We also assayed the twitching activity of the 32 isolates. While twitching was not visible
in all samples, one that displayed such activity was strain PA14, which formed the least
amount of biofilm when compared with other isolates (Figure 9). There were, however,
isolates forming more biofilm coupled with increased twitching activity (CF017, 203097,
Table 2). So, no quantitative correlation was seen between twitching and biofilm
formation.
CF isolates express slow planktonic growth in contrast to efficient biofilm
formation. Biofilm formation could be affected by inherent differences in the planktonic
growth rate of each isolate (92). To measure this growth property, we developed a
method to simultaneously measure the specific growth rate of multiple samples utilizing
the same 96-well microtitre plates used for biofilm formation. P. aeruginosa isolates
grown in this system displayed a typical bacterial growth curve. While the generation
time of CF029 was the lowest and equivalent to 4.8 h (0.15 h-1), PAO1 had the highest
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Figure 9. Motility and twitching activity of P. aeruginosa and the relationship with
biofilm formation and planktonic growth rate. Shown are motility (A) and twitching (B)
zones between 6 isolates and PAO1. The first number under strain designation indicates
the relative fold increase in biofilm formation versus PAO1; number in parentheses
indicates doubling time in h.
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growth rate of about 0.8 h (0.9 h-1) under this condition (Table 2). The CF isolates as a
whole were found to grow significantly slower than non-CF isolates (mean = 0.45 versus
0.7 h-1 respectively; P = 0.008, t test) (Figure 10). When grouped, the CF isolates were
found to form a similar amount of biofilm as non-CF isolates (P = 0.615, t test; Table 2).
Comparatively, biofilm-specific growth of these isolates at different time points also
mimics this trend (data not shown). Furthermore, in comparison with PAO1, the majority
of CF isolates displayed slower planktonic growth but efficient biofilm formation. For
example, the planktonic growth rate of CF005 and CF001 was 3 and 2.3 h-1 respectively,
but they generated 3- and 6-fold more biofilm than PAO1, respectively (Table 2). To
eliminate the possibility of cell partitioning that could be derived from the static culture
method, which may affect the measurement of the planktonic growth rate, a shaken
culture method was also performed. Again, the majority of CF isolates showed the same
trend of reduced planktonic growth rate compared with the environmental isolates, nonCF isolates and reference strains such as PAO1 and PA14. Furthermore, CF isolates such
as CF149, 37 and 46 showed a pattern of fast planktonic growth while CF005, 029 and 25
of slow planktonic growth, consistent with the results obtained with the static culture
method (Table 2). Thus, there was no correlation between planktonic growth rate and
biofilm formation.
No correlation between mucoid phenotype and initial biofilm formation.
Mucoid phenotype, overproduction of alginate, is an important virulence factor in chronic
P. aeruginosa lung infections in CF (43). Recently it has been shown that alginate may
not play a key role in initial biofilm formation (51). A correlation between uronic acid, an
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Figure 10.

Comparison of planktonic growth rate (A) and sensitivity to hydrogen

peroxide (B) between CF and non-CF isolates. Specific growth rates and sensitivity to
H2O2 of each isolate in comparison with PAO1 (star) were determined as described in
Materials and Methods. Line in each group represents the median values of growth rates
(P = 0.008; t test) and growth inhibition zones in mm (P = 0.008; t test).
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alginate precusor, production and initial biofilm formation was tested among different
isolates. As seen in Table 2, the highest alginate producers, CF25, 29 and 37, did not lead
to the highest amounts of biofilm formed in this study. Conversely, some strains with low
alginate production generated high (CFS2, CF005, 226281) and low amounts of biofilms
(CF9, 029). Therefore, no correlation was seen between alginate production and initial
biofilm formation.
Planktonic cells of CF isolates are more sensitive to H2O2. P. aeruginosa
biofilms are more resistant to reactive oxygen intermediates (ROIs) than their planktonic
counterparts (56). However, it is not clear whether individual planktonic cells of
genomically diverse isolates have altered sensitivity to H2O2, an abundant ROI species
within neutrophils. When compared, CF isolates were found to be more sensitive to this
particular ROI species than those of non-CF origin (Figure 10B; P = 0.008, t test).
Non-mucoid CF isolates are associated with reduced lung colonization in an
acute aerosol infection mouse model. To test whether there is a correlation between
increased in vitro biofilm formation and in vivo lung colonization, we utilized an
aerogenic infection mouse model (146). A group of age- and sex-matched C57BL/6 mice
were exposed to aerosols of 7 CF and 3 non-CF isolates (Figure 11). Only non-mucoid
isolates were aerosolized because previous work had indicated that aerosolized mucoid
isolates retained more effectively in the lungs than isogenic non-mucoid strains (145).
Bacterial survival in the lungs was measured for each isolate 6 h after aerosol exposure in
comparison with the initial deposition dose. CF isolates were cleared more effectively (up
to 10% retention) from the murine lungs than non-CF isolates (25-35% retention, Figure
11). PAO1 was markedly less capable of being cleared than the CF isolates tested.
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Figure 11. Nonmucoid CF isolates of P. aeruginosa are cleared more efficiently from the
mouse lungs than non-CF isolates in an acute aerosol infection mouse model. A group of
C57BL/6 mice was exposed to aerosols of different P. aeruginosa isolates as labeled on
the x-axis. For each exposure, five mice each were included for determination of bacterial
deposition to the lungs at t = 0 and 6 h.
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CF isolates have increased genome sizes with genomic insertions. Horizontal
gene transfer is a cause of genomic diversity in P. aeruginosa (5, 65, 67, 123). When the
genomes of the isolates in Table 2 were examined for genomic diversity by SpeI
macrorestriction digestion coupled with PFGE separation (Figure 12A), the isolates
possessed at least one band larger than that of the largest PAO1 fragment (SpeA, Figure
12A). Also, the PFGE banding pattern was highly diverse among these isolates (Figure
12A). This suggests that genome size of these isolates could be hypervariable in relation
to PAO1. To determine whether intrinsic diversity was related to genome size,
chromosomes of these isolates were digested by the homing endonuclease I-CeuI, which
specifically cuts at the rrn operons. A selected group of isolates was analyzed for genome
size (Table 3). As shown in Figure 12B, C, all isolates examined had an equal number of
4 rrn operons, just as PAO1. The genome size of these isolates ranged from 0.4 to 18.9%
larger than that of PAO1 (Table 3). Since many clinical isolates carry specific genomic
sequences called PAGI-1 and -2 (5, 67), we examined the presence or absence of PAGI-1
and -2 by PCR. As shown in Table 3, PAGI-1 and -2 were present within the genomes of
CF149 and 311058, corresponding with the largest genomes identified.
Identification of novel DNA sequences in CF isolates. To identify novel DNA
sequences in these isolates, we developed a simple method based on RAPD coupled with
subtractive hybridization using PAO1 DNA as a probe. While the resolving power of
RAPD mainly allows for strain differentiation (74), it is not made clear what genes are
amplified by this PCR-based method. We hypothesized that some of the randomly
amplified PCR products from the larger genomes could be missing from the PAO1
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Figure 12. Relationship between genome diversity and genome size among clinical and
non-clinical isolates of P. aeruginosa. A. PFGE separation of SpeI-digested chromosomal
DNA from a selected group of P. aeruginosa isolates. Arrow indicates the largest SpeI
fragment of PAO1 (SpeA). B. and C. PFGE separation of genomic DNA digested with ICeuI. Arrows indicate the largest PAO1 fragments, 4,064 and 950 kb, respectively.
Running conditions were (A) 18 h, 6 V/cm, angle 120° in 1% agarose, switch time 15 s to
40 s with a gradient of a=0.35741; (B) 48 h, 2 V/cm, angle 106°, 0.8% agarose, switch
time 20 s to 30 s with linear gradient; (C) 22 h, 6 V/cm, angle 120°, 0.8% agarose, switch
time of 90 s. Molecular size standards: (B) Schizosaccharomyces pombe, (C) Hansenula
wingei (Bio-Rad).
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Table 3. Genomic characteristics of a selected group of P. aeruginosa isolates
Strains Genome size (kb)1 Amt Difference (kb)2 % Difference3 PAGI14
PAO1
6,264
0
0.0
PA14
6,618
354
5.7
CF37
6,862
598
9.6
+
CF149
6,990
726
11.6
+
CF017
6,291
27
0.4
CF032
6,659
395
6.3
CF041
6,386
122
2.0
+
114199
6,875
611
9.8
311058
7,448
1,184
18.9
+
1-3

PAGI25
+
+
+
+

Estimation of genome sizes were performed as shown in Figure 12B,C.
The presence of PAGI-1 and -2 was determined by PCR amplification of the PAGI specific genes. For
PAGI-1 (GenBank # AF241171), three sets of primers were used for PCR. The 1st set amplified the gene
for phytoene dehydrogenase (orf 18:1.5 kb); the 2nd set 1,3 propanediol dehydrogenase gene (orf 22:1.4
kb). Both genes are present only on PAGI-1. The 3rd set produced a PAO1-specific transposase gene
(PA2221, 1.5 kb). +, orf 18/22 present and PA2221 absent. -, PA2221 present but orf 18/22 missing. For
PAGI-2 (Genbank #AF332547), two sets of primers were used; the 1st set amplified the open reading frame
orfA (1.2 kb); the 2nd set produced a partial PAO1-specific gene (PA1089, 0.8kb).
4,5
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genome and may represent unknown genomic islands. A Southern hybridization of a
RAPD membrane with randomly labeled PAO1 genomic DNA yielded two fragments
(1.4 and 2.0 kb) that failed to be hybridized (Figure 13B). Using this method, we
identified 3 novel genomic sequences from two CF isolates, CF005 and CF023 (Table 4).
The CF023-228 sequence was matched to a probable non-ribosomal peptide synthetase
(PA2402) that had homology with the recently released highly divergent pyoverdine
biosynthetic locus from two CF isolates (123). The CF005-275 and -272 sequences were
not present in the GenBank database with the first one encoding a variant of
topoisomerase I from P. aeruginosa and the second encoding a homolog of mvpTA from
Shigella flexneri (111) that has not been identified in P. aeruginosa.
DISCUSSION
Four primary conclusions can be drawn from this cross-sectional analysis of
clinical and environmental isolates of P. aeruginosa. First, various strains P. aeruginosa
have a differing capacity of in vitro biofilm formation. Second, the majority of CF
isolates in comparison with non-CF demonstrate two opposing growth modes: reduced
planktonic growth versus efficient biofilm formation. Third, non-mucoid CF isolates have
a reduced ability of lung colonization compared with PAO1, PA14 and environmental
isolates. Fourth, the presence of novel DNA is common in CF isolates and represents a
major cause of genomic diversity in P. aeruginosa.
Biofilm formation is an important phenotype associated with chronic P.
aeruginosa pulmonary infections in CF (24). In this study, we evaluated the effect of
motility, twitching, growth rate, and alginate on biofilm formation using a group of 32 P.

45

Figure 13. Identification of novel DNA sequences from CF isolates of P. aeruginosa.
A. Randomly amplified PCR products using CF005 as a template with primers as
indicated above the gel were separated in 1% agarose gel. After blotting, filters were
hybridized with random primer-labeled total PAO1 genomic DNA. B. Southern blot of
the gel shown in A with arrows indicating two major bands amplified by primers 272 and
275, respectively, but failed to be bound by PAO1 DNA.
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Table 4. Novel DNA sequences identified from CF isolates of P. aeruginosa
Strain

Primer/insert GenBank
(kb)1
accesssion #

CF005

272/1.5

AY258908

CF005

275/2.1

AY265810

CF023

228/1.6

AY261781

Gene

Homolog product

Plasmid maintenance
mvpTA protein (S. flexneri)
(NP_490590.1)
Topoisomerase I
topA (X. fastidiosa)
(NP_061659.1)
Probable nonribosomal peptide
PA2402
synthetase
(AE004667_1)

1

E value
(Blast
search)
9E-48
4E-50

2E-59

Primers were used as previously described (74). The right number represents the fragments amplified by
this primer, cloned into pCR4-TOPO (Invitrogen) and sequenced with universal M13 primers.
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aeruginosa isolates. A standard method based on bacterial growth within 96-well
microtitre plates (91) was used to assess the biofilm-forming ability of these strains. This
simple method allows for a high-throughput and reliable analysis of biofilm formation on
an abiotic surface. This surface is by no means indicative of CF lungs, however it allows
for analysis of strain-dependent biofilm-forming ability (Figure 8A). Furthermore, the
biofilms formed in this system possess the characteristics of mono- and multi-layer
community structures (Figure 8B). Laboratory strains such as PAO1 and PA14, although
originally isolated from clinical settings (54, 104), have reduced biofilm formation
compared with fresh isolates from clinical and environmental sources. While PAO1 and
PA14 grow optimally as planktonic cells (0.8 and 1.0 h respectively), it appears that the
capacity of biofilm formation in these two strains is at a basal level when compared with
other isolates (Table 2). This is perhaps related to laboratory attenuation of these two
strains. Again, CF isolates form much more biofilm than PAO1 (Table 2). This suggests
that PAO1 may be equipped with endogenous biofilm suppression mechanisms, or
conversely, CF isolates possess mechanisms to promote biofilm formation. Also, most
approaches in studying biofilm formation focus on screening mutants defective in biofilm
formation (90). However, a complementary approach that has not been actively pursued
is to use mutants with increased biofilm formation to identify biofilm repressors in these
two strains. Furthermore, CF isolates are proficient biofilm formers since they exhibit
efficient biofilm formation and despite the fact that they are deficient in planktonic
growth (Figure 10). It is known that P. aeruginosa is capable of making the transition
from an environmental state to a chronic colonizing state in CF (110). However, such an
adjustment comes at a price. For example, most CF isolates are auxotrophic mutants and
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are incapable of synthesizing methionine, leucine, arginine and/or ornithine (6, 7).
Intriguingly, this auxotrophic defect is linked with conversion to alginate overproduction,
known to confer increased resistance to antibiotics and host defenses (43). The
production of alginate in this chronic state is a major consumer of cellular energy in
return for securing the survival of the bacteria. This adjustment and re-routing of cellular
resources to adequately suit the new environment compromises the planktonic growth of
the bacterium (128).
The activity of flagella and type-IV pili has been shown to play a role in biofilm
formation (102). Since all isolates examined in this study had flagella, our results about
the relationship between motility and biofilm formation suggest that the flagellar activity
of CF isolates, as manifested by the observed swimming zones, is not the predominant
factor involving the progressive development of biofilms in vitro. When grouping all
samples in Table 2), a slight correlation was seen between planktonic generation time and
motility (R2=0.30). This trend is expected in that motility, as measured in this study, may
be a reflection of how fast the bacteria are dividing planktonically. This is particularly
evident with PAO1, which has the fastest growth rate and is the most motile (Figure 9A).
Furthermore, twitching as mediated by type-IV pili was not observed in all the tested
samples (Table 2), however many of those without this activity formed more biofilm than
PAO1. This is assuming the twitching assay is a reflection of the role that type-IV pili
play in microcolony formation. Since both assays were inoculated with the same number
of bacteria, the observed variations in these activities could not have been caused by a
difference in the initial inoculum size. Since some CF isolates grow primarily for surface
attachment (Table 2) independent of these two known biofilm-related factors, these
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results suggest the presence of a novel biofilm adhesin. To explain why flagella and typeIV pili activities do not correlate with the amount of biofilm formed, these structural
appendages may only act as biofilm adhesins qualitatively. To support this, a report
showed that increased initial biofilm formation was linked with isogenic variants
deficient in flagella and type-IV pili activities (15, 32). Also, an additional surface
structure called curli has been implicated with increased biofilm formation in an E. coli
K12 mutant (132). However, alginate status of these isolates did not affect initial biofilm
formation in vitro (Table 2), which is in agreement with previous reports that mucoid
exopolysaccharide is needed mainly for maintaining the altered architecture of mature
biofilms (51, 85). Furthermore, although the specific adhesins that promote biofilm
formation on a PVC surface are unknown, our studies showed that the same type of
adhesins are also involved in binding to another abiotic surface, polystyrene. While four
sequential isolates have identical genomic profiles as revealed by PFGE analysis, there
exists a significant variation in biofilm formation, motility, type-IV pili activity, growth
rate, and alginate production among them (Table 2). These isolates may constantly adapt
themselves to changes in the CF lung environment over the course of chronic
colonization. In support of this conjecture, sequential isolates can express differing
phenotypes such as untypable O-antigen (123), and can be either prototrophic or
auxotrophic (6).
When the specific planktonic growth rates of CF and non-CF isolates were
compared, the growth rates of CF isolates were significantly lower (Figure 10). These
results suggest that particular responses taken by CF isolates to evade environmental
stresses begin to tax the cellular resources, at least to a greater extent than the non-CF
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clinical isolates, thereby expressing a reduced planktonic growth rate. The CF lung may
be a more extreme environment to adapt to when compared to other clinical
environments such as burn wounds, therefore manifesting in a reduced planktonic growth
rate. The current work presents a model that while the majority of CF isolates retain their
biofilm-forming ability during their transition from an in vivo to in vitro environment, the
shift from planktonic to biofilm growth may be beneficial to bacterial survival (22).
Association into a biofilm offers a selective advantage allowing the collective unit to
operate as one, protected from the external environment, associated with increased
resistance to antibiotics and host defenses (35), cooperating metabolically and evolving
as a community, potentially by horizontal gene transfer (40).
By inducing a bacterial aerosol-induced lung infection (BAILI) using an
inhalation exposure system (146), a clear distinction in colonization is displayed between
the CF and non-CF isolates (Figure 11). An environmental sample (ERC-1) (124) and
burn patient isolates PA14 (104) and PAO1 (54) all showed increased retention in the
mouse lung compared to the CF isolates. While the biofilm assay determines initial
attachment to a PVC surface, BAILI verifies not only attachment to lung tissue, but also
host defense intervention. The explanation of bacterial clearance from the lung can be
approached in 2 stages. First, the inherent adhesive ability of a bacterial strain determines
whether and how efficiently an initial colonization will take place. This may be due to the
presence of differing bacterial surface structures. For example, CF isolates can express a
novel lipid A portion of lipopolysaccharide (37). Also, fresh clinical isolates fail to bind
to an asialo-GM1, generally considered a lung epithelial receptor for a laboratory strain
(113), indicating CF isolates may have novel surface proteins that mediate attachment to
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lung tissue. Once this colonization exists, the host defenses are the next consideration as
the ability of the isolate to evade clearance is determined. The innate pulmonary defenses
include antimicrobial defensins and neutrophils that carry an abundance of reactive
oxygen species like hydrogen peroxide. Our results suggest that CF isolates, when in the
planktonic phase, are significantly more sensitive to H2O2 when compared with non-CF
isolates (Figure 10B), which showed increased mouse lung retention (Figure 11).
However, a direct catalase enzymatic activity assay on the total cellular extracts of all
these isolates indicated no difference between the CF and non-CF isolates. While this is
inconclusive, the first assay appears to be quantitative and explains the clearance data.
Incidentally, the aerosol mouse model simulates an acute infection condition caused by
planktonic cells, not biofilms. Using this model, bacteria deposited to the alveoli were in
a single cell form (data not shown). Also, neutrophil migration from the blood stream to
the lung occurs within the first four hours following aerosol exposure (145). This may in
part explain why in vivo mouse lung clearance does not correlate with the in vitro
microtitre dish biofilm assay. On the other hand, CFTR knockout mice have recently
been shown to develop lung infections when pre-treated with oral antibiotics (18). It
would be interesting to test the response of this orally treated CFTR mouse model to
aerosolized bacteria to determine whether the modified CFTR-deficient lung environment
affects colonization.
The inherent genomic diversity in P. aeruginosa may be caused by four means of
novel DNA introduction into the bacterial genome: nucleotide substitution, insertions of
transposons and bacterial phages, horizontal gene transfer as well as pre-existing novel
genomic sequences. First, CF isolates of P. aeruginosa often display a high frequency of
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mutation after long-term colonization in CF (93), possibly due to single nucleotide
polymorphisms (SNPs). One example of CF-related SNPs involves mutations in mucA,
giving rise to overproduction of alginate (12). It is known that PAO1 carries transposons
and a bacteriophage (126). Two genomic islands, PAGI-1 and -2, have been identified in
isolates of P. aeruginosa (5, 67). Another consequence of horizontal gene transfer is the
increase in genome size. In this study, we used a low-throughput technique of PFGE to
estimate the genome size of various isolates of P. aeruginosa coupled with a highly
specific digestion using I-CeuI. This method allowed for accurate genome size
determination of P. aeruginosa clone C which was 6.52 Mb, about 256 kb larger (4%)
than the PAO1 genome (112). Using this approach, we determined that a selected group
of isolates in Table 2 had much larger genomes than that of PAO1 (Figure 12). These
results agree with data showing the presence of PAGI-1 and -2 in the largest genomes
analyzed (CF149 and 311058) (Table 2). It has been shown recently that although
extensive novel sequences are present in the genomes of CF isolates, the backbone of the
PAO1 genome is preserved in several P. aeruginosa isolates (65, 123). In combination
with our lung clearance data, this suggests that PAO1 remains an excellent model for
studying virulence even though its genome size is not representative of most CF isolates
(Table 3). Since bacteria in biofilms have an increased incidence of horizontal gene
transfer (40), we also note that while genome size was increased, the lung colonization
ability was reduced in P. aeruginosa CF isolates (Figure 11). This is in agreement with
the trend that a CF isolate had an overall reduction in virulence when examined in a
highly sensitive plant model (117). However, in enterohemorrhagic E. coli O157:H7, the
increase of genome size (19.2%) is associated with increased virulence when compared
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with standard laboratory strain K12 (100). Variations of biofilm formation in different
isolates lead us to speculate whether there are some biofilm-specific genomic islands in
CF isolates. However, the PAO1 genome can be viewed as a mutant. It could be possible
that the ancestor of PAO1 had slowly deleted genes that were not required for specific
environments, thus maintaining only a minimal number of genes (backbone) for P.
aeruginosa survival (123). This view contradicts the concept of novel gene acquisition by
horizontal gene transfer. However, this view can explain why many strains of P.
aeruginosa, including those studied here, have genes not present in PAO1 (65, 123). The
predecessor of PAO1 could have previously possessed many of the genes found
throughout P. aeruginosa isolates, as opposed to the introduction of many novel genes
into PAO1 giving rise to these isolates. Together, what may actually exist could be a
combination of both mechanisms.
Genomic comparison between clinical and environmental isolates can yield useful
information on the inherent virulence properties. While shotgun sequencing of multiple
bacterial genomes is an ideal choice, the costs and time associated are often high. An
alternative is the use of microarray gene expression profiles in conjunction with
subtractive genomic hybridization. However, this high throughput method relies on the
correct annotation of the existing genomes which may carry misannotated genes. To
complement these methods, we developed a simple method that allows for a quick
comparison between two genomes using RAPD in combination with PAO1 DNA
subtractive hybridization (Figure 13). This subtractive method has two key features: i)
RAPD-based amplification of an unknown genome minus ii) the existing PAO1 genome.
Three novel genetic loci were identified in two clinical isolates (Table 4). The mvpAT
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locus is located on a large Shigella virulence plasmid and is involved in plasmid retention
(111). However, the order is reversed (mvpTA) in a CF isolate (CF005). In addition, we
isolated a topA homolog that encodes a topoisomerase I variant. Two topA genes were
found in CF005, one with 100% homology to PA3011 in PAO1 and the other topA
variant that failed to be hybridized by PAO1 genomic DNA. Furthermore, this approach
led us to identify a variant of PA2402 that has been recently hypothesized to be involved
in synthesis of pyoverdine (123). One limitation of this method is the inability to pinpoint
the exact location of these novel genes within the PAO1 backbone, however this can be
resolved by performing inverse PCR. Altogether, RAPD coupled with subtractive
hybridization is an effective way to examine the genomic difference between isolates.
This method also allows identification of smaller DNA segments absent in the PAO1
genome. Variations of this approach with random degenerate primers coupled with
various amplification conditions is expected to generate more novel DNA sequences.
In addition to the improved understanding of the phenotypic diversity with
relation to biofilm formation in P. aeruginosa, this report suggests that the extensive
genomic diversity in this species may become an unexplored cause for the variation in
morbidity and mortality in CF. Furthermore, it demonstrates the presence of multiple
mechanisms of biofilm formation which is aided by novel biofilm adhesin(s) that could
become anti-biofilm therapeutic targets.
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This chapter focuses on a two-component signal transduction system in P.
aeruginosa composed of the sensor kinase KinB and the response regulator AlgB (47). A
sensor kinase is a protein that responds to an environmental signal and phosphorylates the
response regulator. The phosphorylation of AlgB is directed by KinB and results in
alginate suppression.

Conversely, unphosphorylated AlgB leads to alginate

overproduction. Through bioinformatic analysis, AlgB is shown to interact with RpoN.
Unphosphorylated AlgB also interacts at algU to drive alginate production, thereby
establishing the link between this two-component system and algD transcriptional
activity.
ABSTRACT
The production of alginate, an exopolysaccharide, by Pseudomonas aeruginosa is
a poor prognostic indicator for lung infections in cystic fibrosis (CF). The regulation of
alginate synthesis is directed by AlgU, the sigma factor for the algD operon. Various
additional alginate regulators modify the expression of algD. AlgB is a member of a
two-component signal transduction system as the response regulator to the cognate sensor
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kinase, KinB, responding to environmental stimuli.

Previous work has shown that

phosphorylation of AlgB by KinB leads to type-IV pili up-regulation (42). However,
when KinB was removed from the system, AlgB plays a positive role in alginate
synthesis. In this study, we show that AlgB is active in regulating alginate production in
the unphosphorylated form.

AlgB, an orthologue of NtrC in E. coli, is thought to

associate with RpoN (sigma-54), an alternative sigma factor, and also interact at the algU
promoter to regulate gene activity. This study is significant in that the dual-role of this
two-component system is the first found in P. aeruginosa. Further elucidation of this
mechanism and others surrounding the regulation of alginate production can lead to more
defined therapeutic treatments in relation to infections in the CF lung.
INTRODUCTION
Pseudomonas aeruginosa is an opportunistic pathogen responsible for a variety of
acute infections in immunocompromised patients.

Pulmonary infections by P.

aeruginosa in cystic fibrosis (CF) result in the majority of morbidity and mortality due to
respiratory failure. In vivo infections of P. aeruginosa develop into a characteristic
overproduction of an exopolysaccharide called alginate (30). This alginate or mucoid
overproduction phenotype leads to the formation of biofilms, which protects the bacteria
from external stresses such as host responses and antibiotic treatment (101).
Alginate synthesis, directed by the genes within the algD operon, is regulated by a
key alternative sigma factor, AlgU (30). This sigma factor is regulated by gene products
within the algUmucABCD operon (30) as well as regulators elsewhere on the genome.
Mutations in mucA are the most common cause of the mucoid phenotype in CF isolates
(30).
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The cognate sensor kinase for AlgB is KinB, and when phosphorylated, AlgB is
known to up-regulate type-IV pili synthesis (42). This study involved purification of
both AlgB and KinB to show the protein-protein interaction.

Previous work has

suggested an indirect role of AlgB in stimulating algD transcription, but no model has
been established as to how AlgB regulates alginate production (140). This is because no
evidence suggests that AlgB directly binds to the algD promoter.

Even without a

projected mechanism, it has been proposed in a previous study that the phosphorylation
status of AlgB does not affect its activity in alginate production (72). However, in this
previous study, the complete story was masked by the parent strain used, FRD1. While
FRD1, a CF isolate, has been one of the most highly utilized strains of P. aeruginosa for
study, it has a key mutation in mucA (Figure 3) that leaves this strain constitutively
mucoid. If AlgB imparts its function at algD, FRD1 would apparently be a good model
to study the importance of AlgB phosphorylation, because in the signaling cascade of
alginate regulation the FRD1 mutation is in MucA. However, if AlgB acts upstream of
the mucA mutation in FRD1 (e.g. algU), then the constitutive mucoid phenotype of FRD1
would mask the effect that AlgB phosphorylation has on alginate regulation. While the
previous work makes the case for no difference in AlgB phosphorylation at algD in
alginate production, no case is made for a possible interaction of AlgB at algU. To study
this effect completely, a parent strain could be utilized that has a mucoid mutation
upstream of the key regulator of alginate synthesis, AlgU. In this manner, the effects of
AlgB phosphorylation downstream of this key mutation could be studied at algU as well
as at all downstream regulators of the production of alginate.
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In this study, we utilized P. aeruginosa PAO1 mucoid mutants of kinB and algB
to determine how this signal transduction system controls regulation of algD. Through
this work, we show the phosphorylation state of AlgB is important in alginate production.
AlgB actually activates alginate synthesis in a non-phosphorylated form. This form of
AlgB exerts its effect in concert with a previously implicated alginate regulator, RpoN,
through algU. The dual-function of this two-component system reemphasizes the extent
of complex regulation that exists with alginate synthesis in P. aeruginosa.
MATERIALS AND METHODS
Bacterial strains, plasmids and transposons and growth conditions. Bacterial strains,
plasmids and transposons used in this study are listed in Table 5. P. aeruginosa strains
were grown at 37°C in Lennox broth (LB), on LB agar or on Pseudomonas Isolation
Agar (PIA) plates. When required, PIA plates were supplemented with carbenicillin,
tetracycline, or gentamycin at a concentration of 300 µg/ml. For sucrose selection, PIA
plates were supplemented with 10% sucrose. E. coli strains were grown in LB broth or
on LB agar supplemented with carbenicillin (100 µg/ml), tetracycline (15 µg/ml),
gentamycin (13 µg/ml), or kanamycin (40 µg/ml), when required.
Conjugation of plasmids. Equal amounts of donor cells, recipient cells and helper cells
(E.coli pRK2013 – supplies sex pilus) (2 ml each) were combined, pelleted and incubated
on LB plates for 6 h at 37°C. The resulting growth was grown on selective media.
Creation of gene knockouts. To create knockouts of genes in strain VE13, genes of
interest were PCR amplified using XbaI-tailed primers. A Pseudomonas suicide vector
as well as the amplified gene is digested with XbaI, ligated and subjected to random
transposon mutagenesis (EZ::TN <TET-1>) per manufacturer specifications. This
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Table 5. Bacterial strains, plasmids and transposons
Strain, plasmid
or transposon
P. aeruginosa
PAO1

Relevant properties

Reference or
source

Alg-wt, prototroph, genome sequenced and annotated
(www.pseudomonas.com)

PGSC

PAO579

Alg+, PAO381 algU+ mucA+ leu-38 strA2 muc-23 FP2+,
derived from PAO1

J. Govan

VE2

Alg+, PAO1 mucE+oe (himar1Gmr::PGM::mucE)

(36)

VE3

Alg+, PAO1 algU+ (himar1Gmr::algU antisense)
(mucABC)-

(36)

VE8

Alg+, PAO1 mucB- (mucB::himar1Gmr)

(36)

VE13

Alg+, PAO1 kinB- (kinB::himar1Gmr)

(36)

VE19

Alg+, PAO1 mucD- (mucD::himar1Gmr)

(36)

E. coli
DH5α

F- endA1 hsdR supE44 lacZΔM15 recA1

Bethesda
Research
Laboratories

Integration-proficient vector for single-copy chromosomal
lacZ fusion at the attB site

(52)

pRK2013

ColE1 mob tra (RK2) Kmr

(38)

pUCP20

E. coli-Pseudomonas shuttle vector; ori1600, Plac, Apr
(Cbr)

(115)

1.7 kb EZ::TN <TET-1> transposon

Epicentre

Plasmids
Mini-CTX1-lacZ

Transposon
EZ::TN™
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mutant library is mated with PAO1 and selected with tetracycline and 10% sucrose on
PIA. By homologous recombination, the inactive gene then replaces the chromosomal
copy. The gene knockout was confirmed by PCR and sequencing.
DNA sequencing. Purified plasmids and PCR products were sequenced using associated
primers.

Sequencing was performed with 11 μl (approximately 2 μg) of purified

plasmid/PCR product, 1 μl (3.2 pmol) of unlabeled sequencing primer and 8 μl of Big
Dye terminator reaction mix (PE Applied Biosystems). DNA sequencing was performed
on an Applied Biosystems 310 Genetic Analyzer (Foster City, CA) at the Core Facility at
Marshall University School of Medicine. Once the DNA sequences were available, they
were compared by BLAST to GenBank and to the annotation of the PAO1 genome (4).
algU promoter fusions. To fuse the algU promoters 1 and 2 to lacZ, the promoters were
amplified by PCR using HindIII- and EcoRI-tailed primers. The resulting digests were
ligated into HindIII / EcoRI-digested mini-CTX1-lacZ and confirmed by digestion. By
tri-parental mating, algU promoter 1- or 2-mini-CTX1-lacZ was placed on the host
chromosome attB site and confirmed by PCR and sequencing.
β-galactosidase activity assay. The assay was based on the method as originally
described by Miller (81) with the following modification. The cells were grown on PIA
plates in triplicate for 24 h and 48 h at 37°C and harvested in PBS. Cell density was
measured by O.D.600. β-galactosidase activity was assayed after SDS/chloroform
permeabilization of the cells.
RESULTS
KinB-directed phosphorylation of AlgB is associated with alginate
suppression.

To determine if KinB-directed phosphorylation of AlgB leads to
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suppression of alginate in PAO1, we utilized a kinB null mutant, VE13 (36) and a kinB::algB- double mutant.

This mutant produces the alginate phenotype and can be

functionally complemented with reversion of this phenotype (Table 6). To confirm the
role of KinB in the phosphorylation of AlgB, a double knockout was performed. This
kinB and algB null strain was shown to not produce alginate, but complementation with
algB causes reversion of the phenotype to alginate overproduction (Table 6).

No

complementation was seen with a functional kinB in this double mutant. Since strains
with a functional but unphosphorylated AlgB are mucoid, we conclude that
unphosphorylated AlgB is required for alginate overproduction.
AlgB

may

interact

with

RpoN.

Bioinformatic

data

through

www.pseudomonas.com has shown AlgB (PA5483) has a “sigma-54 interaction domain”
signature structural feature (Figure 14). Since the sigma-54 homolog in P. aeruginosa is
RpoN, this suggests that AlgB may interact with RpoN.
RpoN has limited involvement in alginate regulation. RpoN (sigma-54) is
responsible for many cellular processes in P. aeruginosa and has been proposed to be
involved in the production of alginate (10). This previous study implicated RpoN as the
sigma factor for a mucoid, isogenic PAO1 mutant, PAO579. Since AlgB is suggested to
interact directly with RpoN, we were interested in how RpoN might contribute to alginate
regulation. To study this, an rpoN deletion/insertion was introduced into a set of PAO1
mucoid mutants (VE strains; VE2: PA4033-, VE8: mucB-, VE13: kinB- and VE19:
mucD-).

The mutagenesis was performed by inactivating rpoN on a Pseudomonas

suicide plasmid, pED6, and mating this with the VE strains. This mutagenesis resulted in
differing states of alginate production throughout these VE double-mutant strains. VE
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Table 6. Phenotypic characteristics of the effects of KinB and AlgB on alginate
Strains
Alginate Phenotype1
PAO1 + pUCP20
NM
2
VE13 + pUCP20
M
VE13 + kinB/pUCP20
NM
VE13 algB- + pUCP20
NM
VE13 algB + algB/pUCP20
M
VE13 algB- + kinB/pUCP20
NM
2

1

Phenotype is scored visually on PIA plate media as non-mucoid (NM) or mucoid (M); VE13
genotype is PAO1 kinB .
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Figure 14. Sigma-54 interaction domain in AlgB. Shown is the protein sequence of
AlgB.

The underlined portion indicates the sigma-54 interaction domain structural

feature.
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strains which were defective in KinB and PA4033 product (VE13 and VE2, respectively)
reverted to the non-mucoid phenotype upon rpoN disruption. This suggests that RpoN
has a positive effect on the regulation of alginate, as part of the regulation cascade
preceding algU.

These VE mutants, therefore, displayed a reliance on RpoN in

producing alginate. On the other hand, the mutants acting downstream of algU showed
no need for RpoN when producing alginate. PAO1 VE mucoid mutants of mucB and
mucD (VE8 and VE19 respectively) did not change phenotype when rpoN was disrupted.
Taken together, these findings suggest RpoN is essential for alginate production in VE13
and VE2 and may act in concert with AlgB when controlling the expression of alginate
regulation genes. All double-knockouts were complemented with a functional rpoN with
phenotypic reversion. Interestingly, multiple attempts to create a double-knockout of
rpoN in VE3 (mucABC-) were unsuccessful. This suggests RpoN is essential in the
mucABC- background. Altogether, RpoN appears essential in alginate regulation, in the
context of VE13 and VE2.
Absence of KinB results in algU activity. AlgB is active in alginate regulation
only when phosphorylated by KinB. Based on the suggested interaction between AlgB
and RpoN as well as the apparent selective role of RpoN in alginate regulation, a
hypothesis was formed that absence of KinB activity is required for activity at algU. To
test whether loss of KinB activates algU to therefore drive transcription of algD, we
created algU-lacZ promoter fusions to determine the extent of KinB involvement. The
algUmucABCD operon is preempted by five promoters. Promoters 1 and 3 are known to
be AlgU auto-regulating promoters (114), while promoters 2, 4 and 5 have yet to be
implicated in alginate regulation. Since the activity of promoter 2 is unknown and can be
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easily combined with promoter 1 for analysis, we chose promoters 1 and 2 for algU
promoter fusion activity assays (Figure 3). In some assays, fusions of promoters 1 and 2
together were tested for activity. The strain tested was VE13.

After analysis,

comparisons between the VE13 strain variations showed significant results (Table 7,
Figure 15). For VE13 and VE13 + kinB/pUCP20, promoter 2 almost doubled activity
compared to promoter 1 at both 24 and 48 h time points. VE13 strains showed increased
activity at the 24 h point compared with VE13 + kinB/pUCP20. Also, addition of
multiple copies of algB did not change the activity of promoters with VE13 P2-P1-lacZ.
To summarize, the VE13 strains had activity through both algU promoter 1 and 2. This
shows that loss of KinB results in algU promoter activity. Although this study is not
completed, current studies are ongoing with VE13 rpoN-, VE13 algB- and PAO1 rpoNstrains along with related complementations.
DISCUSSION
Through these studies, it has been shown that the phosphorylation state of AlgB
determines whether alginate is produced in PAO1. The disparity with the previous work
(72) was that the parent strain in the study had a phenotype that masked the real result of
the AlgB phosphorylation.

The exclusive interaction between KinB and AlgB has

previously been determined, and no additional kinases or phosphodonors have been
implicated in AlgB phosphorylation (72). While phosphorylated AlgB up-regulates typeIV pili, it also plays a dual role as it up-regulates alginate in the unphosphorylated form.
This dual role has been seen previously in two-component systems of other organisms.
In Bacillus subtilis, the DegS-DegU two-component system controls genes involved in
expressing degradative enzymes and late-competence proteins (63). With this system,
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Table 7. KinB-AlgB promoter fusion table
Strains1
VE135 P1-lacZ + pUCP20
VE13 P2-P1-lacZ + pUCP20
VE13 P1-lacZ + kinB/pUCP20
VE13 P2-P1-lacZ + kinB/pUCP20
VE13 P2-P1-lacZ + algB/pUCP20
1

24h
48h
1874.48 1884.91
4003.20 3592.83
369.69
n/d4
944.47 759.76
3473.18 3249.83

24h SD2
34.55
193.34
7.79
4.86
404.19

48h SD2
342.50
710.90
n/d
58.70
71.06

Alginate3
+
+
+

All VE13 promoter fusions tested are listed here; all showed activity; 2standard deviation; 3Alginate
4
5
overproduction; n/d – not determined; VE13 genotype is PAO1 kinB .

67

Figure 15. algU promoter fusion assays for VE13 strains. lacZ activity was measured in
Miller Units at 24 h (dark bars) and 48 h (white bars) post-inoculation. VE13 P2-P1-lacZ
+ algB/pUCP20 represents overproduction of algB.

Data for VE13 P1-lacZ +

kinB/pUCP20 48 h not available. VE13 genotype is PAO1 kinB-.
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phosphorylated DegU is required for expression of genes encoding degradative enzymes,
as well as degQ, degR and srfA.

A DegU derivative unable to be phosphorylated

abolished this activity. Unphosphorylated DegU activates late-competence genes comC
and comG (63). This system, like KinB-AlgB, acts as a molecular switch, turning genes
on and off based on molecular modification by phosphorylation, as previously suggested
(72).
In all of the VE13 parent strains with functional rpoN and algB genes, activity
was seen (Table 7, Figure 15). In the case of VE13 and VE13 + kinB/pUCP20, the
addition of promoter 2 almost doubled the activity when compared to promoter 1 alone
for both the 24 and 48 h time points. This shows some enhanced activity as a result of
the addition of the P2 to P1 in the VE13 background. Also, there was an enhanced
response in the mucoid VE13 strains compared with VE13 + kinB/pUCP20 at the 24 h
time point. The activity at P2-P1 must be higher when the AlgB is unphosphorylated and
decreases when a functional KinB inactivates AlgB. Notably, the VE13 P2-P1-lacZ
activity did not change with addition of multiple copies of algB/pUCP20 at both time
points. In VE13, it is likely when AlgB is unphosphorylated and active at the algU
promoter, that the system is saturated and no additional activity can be seen with more
AlgB. Some activity is seen, however with the non-mucoid VE13 + kinB/pUCP20. This
activity is most likely due to the chromosomal copy of algU auto-regulating itself
through not only the chromosomal algU promoter but through the algU promoter-lacZ
fusions. Overall, this assay shows not only that the absence of KinB generates activity at
the algU promoters 1 and 2, but also that activity at P2 is enhanced. Future studies can
focus on what role RpoN plays directly in the regulation of alginate. So far, only its

69

interaction with AlgB has been determined. RpoN is a sigma factor responsible for many
cellular regulatory processes (10). RpoN could also be acting in other areas of the cell to
assist in the control of alginate production. A proposed model places unphosphorylated
AlgB at P1 and P2 of algU, potentially in concert with RpoN (Figure 16).
KinB, the cognate sensor kinase for AlgB is an important negative regulator of
alginate production. This is shown by the absence of activity at the algU promoters in
the presence of KinB. Along with RpoN, AlgB represents an essential player in the
alginate regulation pathway. These two proteins interact, but the absence of KinB is
shown to direct the expression of algU through the algU promoters 1 and 2. This
discovery furthers the knowledge regarding the extent of the alginate pathway and the
inclusion of a novel dual-role two-component system.
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Figure 16. Old model and proposed model for interaction of KinB, AlgB and RpoN in
the regulation of alginate production. The old model proposed that the phosphorylation
state of AlgB did not matter when up-regulating algD expression through some other
factor. The proposed model involves positive interaction of unphosphorylated AlgB at
the P1 and P2 promoters of algU, possibly requiring RpoN for the promoter interaction.
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CHAPTER 4. IDENTIFICATION AND ANALYSIS OF NOVEL ALGINATE
REGULATORS RELATED TO BIOFILM FORMATION IN Pseudomonas
aeruginosa
This chapter focuses on three approaches taken to further identify and classify
novel alginate regulators from the PAO1 genome related to P. aeruginosa biofilm
formation. Two of the approaches involve using a PAO1-derived cosmid library to
classify the unknown alginate locus in PAO1 isogenic mucoid mutant PAO579 (muc-23)
and the known locus in PAO568 (mucA2). From this approach, five alginate-controlling
loci were located within the PAO1 genome.

Another approach addresses an existing

regulator in the alginate regulation pathway, MucD. Specific experiments were devised
to determine the functional regions of MucD in alginate suppression and temperature
sensitivity.
ABSTRACT
Alginate production by Pseudomonas aeruginosa is partially responsible for its
ability to evade host defenses in the CF lung. While much of the alginate regulatory
pathway has been elucidated, some unknown factors contributing to the production of
alginate still exist. Utilizing two PAO1 isogenic mutants PAO579 (muc-23) and PAO568
(mucA2) with mutations of unknown and known origin, respectively, the PAO1 genome
was scanned for the location of these mutations. By way of a PAO1-derived minimal
tiling path cosmid library, four and one cosmid(s) complemented the mucoid phenotype
of PAO579 and PAO568, respectively. The individual loci within PAO579 were located
by random transposon mutagenesis of the complementing cosmids with reversion of the
phenotype.

These loci were given the names muiA-D.
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Alongside the novel gene

identification, further classification was given to MucD, an anti-sigma factor to the
alginate sigma factor AlgU. By way of protein truncation, the action of MucD, as an
anti-sigma factor controlling alginate production, required the protease domain and at
least the first PDZ binding domain. For its temperature-sensitive functionality, growth
was hindered with only the protease domain and no PDZ domain, and disruption of the
protease domain resulted in no growth.

Taken together, these studies address new

biofilm regulators in the scope of alginate production, present within the PAO1 genome.
Also, a known alginate suppressor was further investigated to elucidate its specific role in
regulation of alginate.

These findings of novel biofilm regulators and protein

functionality can help further the understanding of the entire alginate regulation pathway
in P. aeruginosa.
INTRODUCTION
In the search for novel biofilm formation inhibitors, an approach was taken to
address the regulation of alginate formation. Because alginate is strictly required for the
formation of the mature biofilm structure, inhibition of alginate production would result
in reduced biofilm formation. The alginate regulatory pathway of P. aeruginosa centers
on AlgU, a sigma factor for the alginate biosynthetic operon. Another pathway is RpoNdependent as seen in PAO579 (muc-23), a mucoid, isogenic mutant of PAO1 (9).
Although RpoN directs transcription of the alginate operon and aids in alginate
overproduction, the related muc-23 allele is unknown (8). To determine the location of
the muc-23 locus, a PAO1-derived minimal tiling path cosmid library was used to
complement the mutation with reversion of the phenotype.
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This study yielded the

identification of four novel loci within the PAO1 genome responsible for alginate
regulation.
The origin of the mucoid mutation for PAO568 (mucA2) is in mucA, a gene
encoding an anti-sigma factor required for the repression of alginate production (39).
However, it was of interest to determine whether the PAO1-derived cosmid library had
an effect on the alginate phenotype by way of a potential difference in expression levels
of particular genes. For this reason, PAO568 was also tested with the PAO1-derived
cosmid library. This study led to the identification of a cosmid complementing the
mucA2 mutation, however did not overlap the mucA region of the PAO1 genome.
For further elucidation of the regulatory mechanisms of alginate production in P.
aeruginosa, numerous factors still require attention in order to appropriately understand
their specific role in this pathway. One such candidate is MucD. This protein, which is
encoded from the algUmucABCD operon, is a negative regulator of alginate synthesis.
MucD is a molecular chaperone with a protease function (Figure 3). P. aeruginosa
mutants in mucD are susceptible to heat killing at 50°C and have shown significantly
reduced growth ability at 42°C (8). MucD displays a typical leader peptide feature,
thereby possibly localizing it to the periplasm (8). When in place, it may use its protease
function to aid in protein folding or degredation. The absence of MucD, such as when
mucD is inactivated, leads to a mucoid phenotype in PAO1. Therefore, MucD may play
a direct role in controlling the level(s) of protein within the periplasmic space that are
somehow responsible for alginate regulation. In E. coli, the MucD homolog, HtrA,
degrades periplasmic proteins and is also temperature sensitive (69). MucD possesses
one protease domain and also two PDZ domains, which are responsible for binding the
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target of interest for proteolytic cleavage. It has been shown that dual PDZ domains
assemble in a barrel-like structure within which the protease domain can degrade specific
target proteins (82). Therefore, the absence of one or both of the PDZ domains or the
protease domain may result in the inactivity of this protein, either in mucoid regulation or
heat sensitivity. This study was performed to determine the functional domains of MucD
responsible for binding to the factor(s) involved in alginate production.
MATERIALS AND METHODS
Bacterial strains, plasmids and transposons and growth conditions. Bacterial strains,
plasmids and transposons used in this study are listed in Table 8. P. aeruginosa was
grown on Pseudomonas Isolation Agar (PIA) supplemented with 300 µg/ml tetracycline,
or in Lennox broth (LB) with 50 μg/ml tetracycline, when required. E. coli was grown in
LB or on LB agar (1.5%) supplemented with 100 µg/ml ampicillin, 40 µg/ml kanamycin,
or 20 µg/ml tetracycline, when required. All incubations were carried out at 37 or 42°C
where noted. PAO9DE is a PAO579 merodiploid strain that carries the endogenous algD
gene and a chromosomal copy of the algD promoter fused with reporter gene xylE. CF15
and 22 are CF clinical sputum isolates. A minimal tiling path (MTP) cosmid library
comprising 93.7% of the P. aeruginosa PAO1 genome (55) was provided by Dr. P.
Phibbs from the Pseudomonas Genetic Stock Center (PGSC) at East Carolina University.
Each member of this library, which is maintained within four 96-well microtitre plates,
has a 20-30 kb DNA fragment mapped to its respective position within the PAO1
genome. This library was constructed by Sau3AI partial digestion of the PAO1
chromosomal DNA followed by cloning these fragments into the BglII site of the Kmr
gene in the broad-host-range vector pLA2917 (2).
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Table 8. Bacterial strains, plasmids and transposons
Strain, plasmid
or transposon
P. aeruginosa
PAO1

Relevant properties

Reference or
source

Alg-wt, prototroph, genome sequenced and annotated
(www.pseudomonas.com)

PGSC

PAO579

Alg+, PAO381 algU+ mucA+ leu-38 strA2 muc-23 FP2+,
derived from PAO1

J. Govan

PAO568

Alg+, PAO381 algU+ mucA+ leu-38 strA2 mucA2 FP2+,
derived from PAO1

J. Govan

Alg+, PAO381 algU+ mucA+ leu-38 strA2 mucA22 FP2+,
derived from PAO1

J. Govan

PAO9DE

PAO579 algD+ algD-xylE

This work

CF15

mucA22

(12)

CF22

mucA22

(12)

VE19

Alg+, PAO1 mucD- (mucD::himar1Gmr)

(36)

E. coli
DH5α

F- endA1 hsdR supE44 lacZΔM15 recA1

Bethesda
Research
Laboratories

recA thi pro hsdR RP4-2-Tc::Mu Km::Tn7

PGSC

IncP1 mob tra cos Kmr Tcr

(2)

pHYDX

pCMobB algD-xylE mob Apr (Cbr)

(149)

pRK2013

ColE1 mob tra (RK2) Kmr

(38)

pVDtac24-mucA+

(77)

1.2 kb EZ::TN <KAN-2> transposon

Epicentre

PAO578

S17-1
Plasmids
pLA2917

ptacmucA
Transposon
EZ::TN™
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Pulsed-field gel electrophoresis (PFGE). PFGE analysis of genomic profiles of P.
aeruginosa isolates was adapted from the standard enterobacteria procedure developed by
CDC (PulseNet, Section 5, Preparation of PFGE Plugs from agar cultures,
www.cdc.gov). Briefly, P. aeruginosa overnight culture (5 ml) was pelleted and
resuspended

in

1

ml

cell

suspension

buffer

[100

mM

Tris;

100

mM

ethylenediaminetetraacetic acid (EDTA), pH 8.0] to 10% transmittance as indicated by
the BioMerieux Vitek colorimeter. The cell suspension (200 μl) was combined with 200
μg proteinase K and inverted 6 times. A mixture of 1.6% InCert agarose (FMC
BioProducts, Rockland, ME) and 1% sodium dodecyl sulfate (SDS) [1.6% Incert/1%
SDS mixture: 0.8 g InCert agarose; 2.5 ml 20% SDS; 46.7 ml Tris-EDTA buffer (TE)]
(200 μl) was mixed with the cell suspension/proteinase K mixture and dispensed in an
agarose plug mold (Bio-Rad). After solidifying, the cells were lysed within the plug using
1.5 ml cell lysis buffer (50 mM Tris; 50 mM EDTA, pH 8.0; 1% N-Lauroylsarcosine)
and 800 μg proteinase K for 1.5 h in a 54°C water bath with agitation. Plugs were then
washed twice with 10 ml pre-heated, sterile, reagent grade H2O for 15 minutes and twice
with 10 ml pre-heated TE buffer for 15 min, with all washes performed in a 48°C water
bath with agitation. Portions of the plugs (1.5 mm) were digested with restriction enzyme
SpeI (10 U) or XbaI (100 U) for 1 h at 37°C. Digested portions were loaded into an
agarose gel of certain concentration and subjected to certain separation conditions, both
noted in the pertaining figure. The running buffer was 0.5X Tris-Borate EDTA (TBE).
After PFGE, the gel was stained with ethidium bromide (1 μg/ml) for 30 min and
photographed under UV light.
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Whole-genome complementation. The MTP cosmid library was used to complement
alginate overproduction in PAO579 and PAO568. This library was grown overnight by
diluting 10ul of original culture from the master plates with 140 ul LB supplemented with
tetracycline in a 96-well microtitre plate and incubating at 37°C overnight at static
conditions. Overnight culture of PAO579 (150 ul) was combined with each member of
the library within the microtitre dish using an 8-channel transfer pipette. The entire
volume of each mixed culture was then passed through a vacuum-assisted manifold
containing a nitrocellulose membrane in a 96-well format, thereby depositing the mixture
of donor and recipient cells onto the membrane. The membrane was incubated on 100 x
15 cm LB plates overnight at 37°C. Each individual conjugation was streaked for
isolation on PIA with tetracycline and incubated at 37°C for 48 h for phenotypic scoring.
Conjugation of plasmids. Equal amounts of donor cells, recipient cells and helper cells
(E.coli pRK2013 – supplies sex pilus) (2 ml each) were combined, pelleted and incubated
on LB plates for 6 h at 37°C. The resulting growth was grown on selective media.
In vitro transposon mutagenesis. Selected MTP cosmids were purified using a Qiagen
Maxi Prep kit. In vitro transposon mutagenesis of the cosmids was performed using the
EZ::TN <KAN-2> insertion kit. The transposon-inserted cosmids were transferred into
DH5α cells and selected on LB plates with kanamycin. Mutant library was scraped from
the plate, washed in 1 ml LB and transferred en masse to PAO579 or PAO568 by
triparental mating with pRK2013. Transconjugants were selected on PIA with
tetracycline and screened for reversion to the mucoid phenotype, i.e. loss of function
mutations. These Pseudomonas colonies were grown in 2 ml LB with tetracycline at
37°C overnight. Plasmid miniprep isolated mutant cosmids which were transferred back
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into DH5α and selected for on LB plates with kanamycin. The mutant cosmid was
propagated using Qiagen Maxi prep.
PCR procedures. The temperature cycling that used a BioRad iCycler system was as
follows: 94°C for 1 min, 34 cycles consisting of 94°C for 1 min, 54°C for 2 min (55°C for
inverse PCR), and 72°C for 2 min, and a final extension step consisting of 72°C for 8
min.
DNA sequencing. PCR products were sequenced using associated primers. Sequencing
was performed with 11 μl (approximately 2 μg) of purified plasmid/PCR product, 1 μl
(3.2 pmol) of unlabeled sequencing primer and 8 μl of Big Dye terminator reaction mix
(PE Applied Biosystems). DNA sequencing was performed on an Applied Biosystems
310 Genetic Analyzer (Foster City, CA) at the Core Facility at Marshall University
School of Medicine. Once the DNA sequences were available, they were compared by
BLAST to GenBank and to the annotation of the PAO1 genome (4).
Alginate and enzyme assay. The alginate assay was performed as previously described
(48) except with the following modifications. After incubation on PIA plates at 37°C for
48 h, harvest confluence growth by resuspending in 10 ml 1X PBS and pellet cells at
3,000 rpm for 30 min. An alginate standard curve was derived from sodium manuronate.
To determine total protein, resuspend the cell pellet in 500 μl of 4°C 50 mM KPB pH 7.5
10% acetone and dispense into a clear cryotube filled with 250 μl 0.5 mm zirconia/silica
beads. Bead beat for 60 s x 3 while on ice. The supernatant was measured for protein
concentration using the DC Protein Assay. The catechol 2,3-dioxygenase (CDO) assay
was carried out by combining 2.5ml H2O, 0.3ml 0.5M KPB pH 7.5 and 0.1 ml 10 mM
catechol into a cuvette. Add 10 ug cellular protein supernatant, invert to mix and perform
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a kinetics assay by reading samples at 375 nm for a total duration of 120 s, taking
readings in 5 s intervals. The molar extinction coefficient of the reaction product,
2-hydroxymuconic semialdehyde, is 4.4 x 104. One unit of CDO is defined as the amount
of enzyme oxidizing 1 μmol of catechol per min at room temperature.
RESULTS
The mutation responsible for alginate overproduction in PAO1 isogenic
mutants is not due to chromosomal translocations. To determine which molecular
mechanism is predominant in the cause of conversion to mucoid, the genomic profiles of
PAO1, PAO579 and PAO568 were analyzed using macro-restriction digestions of their
respective genomes coupled with separations in a PFGE system (Figure 17). It is
concluded here that conversion to mucoid is not associated with large genomic
translocations.
Identification of four complementing cosmids for the muc-23 mutation. To
search for the muc-23 mutation, a comprehensive complementation approach was taken
which allowed for a complete genomic scan for mucoid biofilm inhibitors by alginate
phenotypic screen. A PAO1-derived genomic minimal tiling path (MTP) cosmid library
(55) was introduced into P. aeruginosa PAO579. Biparental conjugation allowed the
transfer of each cosmid from the donor E. coli strain into the recipient PAO579 followed
by selection of non-mucoid transconjugants (Figure 18). In the initial screen, a total of 22
clones were found with a mucoid-suppressing function. Three pairs of them had
overlapping regions in the genome (MTP164/165: 18.4 kb; MTP188/189: 22.0 kb;
MTP302/303: 19.0 kb). After prolonged incubation (>5d) however, most of these 22
clones displayed a partial complementation pattern with the majority of colonies non-
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Figure 17. Genomic profiles among the isogenic strains of PAO1. PFGE separation of
the whole genomes digested with restriction endonucleases SpeI or XbaI. Running
conditions were 18 h, 6 V/cm, angle 120° in 1% agarose, 3 to 20 s switch times with a
ramping gradient of 0.24297 (left) and 5 to 20 s switch times with linear gradient (right).
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Figure 18.

A conjugation-based complementation approach for identifying novel

mucoidy inhibitor genes within the P. aeruginosa PAO1 genome. Shown is a nylon
membrane with spots of growth. Each spot is an individual conjugation including the
donor E. coli S17-1 carrying the cosmid library and recipient P. aeruginosa PAO579
incubated overnight at 37°C on a nylon membrane on a large LB plate.
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mucoid but a small fraction emerged with mucoid colony morphology. These cosmids
were eliminated from further consideration.

Finally, four clones that completely

suppressed the mucoid phenotype in PAO579 were identified: cosmids MTP87, 164, 268
and 307 (Figure 19). Unexpectedly, under non-inducing conditions, the mucA gene
regulated by a lac promoter on a plasmid was capable of suppressing mucoid in PAO579
when present in trans (Figure 19).
Identification of specific loci within each cosmid responsible for alginate
suppression. The next hypothesis was that inactivation of the mucoid-related genes
within these cosmids would result in restoration of the alginate phenotype after
complementation. To test this hypothesis, an EZ::TN transposon was used to in vitro
mutagenize these cosmids. Individual banks of mutant clones carrying transposon
insertions within cosmids MTP87, 164, 268 and 307 were conjugated en masse into
PAO579 followed by screening for colonies with mucoid morphology (Figure 20). While
the majority of transconjugants were non-mucoid, some were mucoid, indicative of the
apparent transposon-mediated inactivation of specific mucoid inhibitor genes. DNA
sequencing of a mutant MTP87 clone confirmed a single transposon insertion into an
ORF PA1494, which resulted in loss of mucoid-suppressing function. Since PA1494
belongs to a class of unclassified/hypothetical genes in the database, it was named
mucoid inhibitor gene A, or muiA. The muiA gene encodes a polypeptide of 551 amino
acids with a predicted molecular mass of 61 kDa and isoelectric point (pI) of 5.5. Located
immediately downstream is an E. coli periplasmic sulfate-binding ortholog gene (cysP:
PA1493). The muiA gene may use GTG as a start codon with a typical signal sequence
encoding 22 amino acids (NH2-MNRLAASPLLFAGLFASAPLLA-COOH). Through
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Figure 19. Mucoid suppression in muc-23 cells by the selected four MTP cosmids.
Shown are PAO579 carrying the alginate-suppressing cosmids. 1 - negative control –
mucoid; 2 - MTP87 – nonmucoid; 3 - MTP164 – nonmucoid; 4 - MTP268 – nonmucoid;
5 - MTP307 – nonmucoid; 6 - ptac-mucA+ (mucA on plasmid shown complementing the
mucoid phenotype) – nonmucoid.
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Figure 20. A non-overlapping cosmid library, derived from the Pseudomonas aeruginosa
reference strain PAO1 was conjugated to mucoid derivatives of PAO1 (PAO579, muc-23;
PAO568, mucA2). Those cosmid clones suppressing mucoidy were chosen for in vitro
random transposon insertion, consisting of a combination of a Tn transposon in the
presence of transposase. This mutagenesis reaction will inactivate target genes in order
to restore the bacterium to the original phenotype (shown in inset picture; circles show
mucoidy restoration).

Once this clone is identified, flanking regions of the Tn are

sequenced to locate its insertion point on the PAO1-derived cosmid. This potential
mucoidy inhibitor will then be isolated by PCR from the PAO1 genome and used to
suppress mucoidy in the original strain.
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BLAST analysis, MuiA orthologs were found in other organisms including Rhodobacter
capsulatus, Bradyrhizobium japonicum, Nostoc sp., and Caenorhabditis elegans. These
homologs were all of similar size ranging from 530 to 560 amino acids in length. An
internal region of MuiA (232-274) displayed 3 highly conserved domains (Figure 21). In
addition, the transposon insertion in MTP87 was located 15 bps in front of these
conserved domains (Figure 21).
Using the same approach as with MTP87 (Figure 20), three additional candidate
genes, muiB-D, were located within the identified cosmids (Table 9). A single transposon
insertion in MTP164 was found at 2 bps following the 3’ end of endA with an 18 bps
intergenic region. As predicted, this transposon insertion occurred within the overlapping
region between the two complementing cosmids MTP164 and 165. Since the EZ::TN
transposon used here had a strong transcription terminator, PA2750, the gene located
immediately downstream of endA was named muiB. Based on the annotation of the
PAO1 genome, a 726 bp intergenic noncoding region was noted between muiB and its
downstream ORF, PA2751, whose function was also hypothetical. The function of muiB
is unknown except for its association with alginate suppression and its encoding a small
protein of 172 amino acids with a predicted molecular mass of 19 kDa and pI of 8.3. In
addition, the N-terminal 100 amino acids of MuiB showed 50% similarity to a putative
partition protein from Salmonella typhi (AAF69991). According to analysis using the
signal

peptide

prediction

algorithm

from

http://bioinformatics.leeds.ac.uk/

prot_analysis/Signal.html, MuiB had a higher probability than MuiA (13.1 vs. 12.2) to
possess

a

leader

peptide

which

consisted

MIFRTLALLPLCAALAFA-COOH).
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amino
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Figure 21. Identification of the muiA gene. A. Restriction map, gene organization and
transposon insertion in muiA. B. Homology of MuiA with its orthologs in different
organisms. Shown are the most homologous regions (1, 2 and 3) which could serve as a
putative functional domain. Nostoc sp. (NOS; NP_484904; 545 aa), B. japonicum (BJ;
CAC38742; 560 aa), R. capsulatus (RC; ORF1654; 534 aa), and C. elegans (CE;
NP_500427; 556 aa). A single EZ::TN transposon insertion occurred upstream of regions
1, 2 and 3.
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Table 9. Four muc-23-specific mucoid inhibitor genes in PAO1
MTP
#1
87
164
268

Genomic
Start2
1,618,021
3,103,879
5,049,705

Genomic
End2
1,640,777
3,126,161
5,073,757

Identified
Gene3
muiA
muiB
muiC

307

5,770,666

5,792,471

muiD

1,2

PA Alternative Other Function
GenBank
#4
Name
Accession #
1494
AF226874
2750
4512
LPS biosynthetic
lpxO1
protein
5142
Glutamine
hisH1
amidotransferase

The PAO1 genome was arrayed in a total of 338 minimal overlapping cosmids (55). Start and end
positions of each insert within the MTP cosmid were mapped to the database at www.pseudomonas.com.
3,4
As illustrated in Figure 20, transposon insertion sites coupled with the loss of the complementation ability
were identified. The genes so identified were named mucoid inhibitor A-D (muiA-D).

88

A transposon insertion in PA4512, which encodes a putative dioxygenase
required for the biosynthesis of lipid A, abolished the mucoid-suppressing function in
MTP268. Thus, PA4512 was named muiC, which encodes a protein of 299 amino acids
with a predicted molecular mass of 35 kDa and pI of 9.9. Another single transposon
insertion at 259 bps downstream of the start codon of ORF PA5142 (full length = 639
bps) inactivated the mucoid-suppressing function in MTP307. PA5142 is also known as
hisH1 which encodes an enzyme (glutamine amidotransferase) essential for histidine
biosynthesis in E. coli. However, unlike E. coli K12, the PAO1 genome carries two hisH
paralogs, hisH1 (PA5142) and hisH2 (PA3152). The first hisH cluster, located in the late
region of the genome, consists of 4 genes hisBH1AF1. The second hisH cluster, located
within the middle of a lipopolysaccharide (LPS) biosynthetic cluster (wbpA-wbpL),
consists of 2 genes, hisH2F2. Consistent with other nomenclature related to the observed
function, the hisH1 gene was renamed muiD, which encodes a polypeptide of 212 amino
acids with a predicted molecular mass of 24 kDa and pI of 5.9. Another histidine
biosynthetic enzyme, imidazoleglycerol-phosphate dehydratase (hisB or PA5143), is
located upstream of muiD. The stop codon (TGA) of hisB overlaps with the start codon
(ATG) of muiD. Furthermore, based on the bioinformatic analysis of signal peptide
prediction, neither MuiC nor MuiD has a leader sequence at their N-termini, indicative of
their cytoplasmic location and is compatible with their known function in LPS and
histidine biosynthesis.
Activity of cosmid complementation shows suppression of algD promoter
activity. Since the activation of algD expression initiates a series of events leading to
alginate overproduction, it is possible to measure the effect of these newly identified
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cosmids on the transcriptional activity of the alginate biosynthetic operon (Figure 3). To
do so, a PAO579 recombinant strain (PAO9DE) was generated that carried a
chromosomal copy of the algD promoter fused with a reporter gene, xylE, encoding a
catabolic enzyme (CDO), while the endogenous algD gene remained intact within the
strain and was therefore used for alginate overproduction. This merodiploid strain was
made using a construct pHYDX (149) that allowed plasmid integration into the genome
via a single cross-over event. Since PAO9DE displayed a mucoid phenotype, it produced
increased specific activity of CDO which directly correlated with algD promoter activity
(Figure 22). Again, the 4 MTP cosmids containing muiA-D along with the wild-type
mucA gene suppressed mucoid in PAO579 and PAO9DE, respectively. No difference
was seen in the amount of alginate produced in the presence of these plasmids containing
muiA-D and mucA, further confirming that mucA complements the muc-23 mutation.
Furthermore, the algD transcriptional activity was reduced to a basal level when these
plasmids presented in trans. As expected, a negative control (MTP289), which was
randomly selected from the library, had no effect on mucoid and algD transcription.
Determining the effect of complementing cosmids on mucoid clinical CF
isolates. Since the 4 MTP cosmids (Table 9) were able to independently complement the
muc-23 allele, it was of interest to determine whether the muc-23 allele was present in
clinical CF mucoid isolates. Two mucoid isolates, CF15 and CF22 (12), were selected
because both carried the same mucA22 allele, the most common mucA mutation with a
deletion of a G at 440, which can be complemented by mucA. When the 4 cosmids
carrying muiA-D were provided in trans, the mucoid phenotype of CF22 converted to
non-mucoid (data not shown), while the mucoid status of CF15 was not affected by the
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Figure 22.

Alginate and XylE assays for MTP cosmids that complement mucoid

phenotype in PAO579 (muc-23). Effect of MTP cosmids on alginate production and the
algD transcriptional activity in muc-23 cells. MTP289 is a randomly selected negative
cosmid control.
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presence of the cosmids. Therefore, it is possible that the muc-23 mutation represents
another cause for conversion to mucoid in clinical CF mucoid isolates.
Identification of complementing cosmid for the mucA2 mutation.

To

determine whether there is a phenotypic effect of the PAO1-derived cosmid library on
PAO568 (mucA2), similar methods were used as with PAO579.

Whole-genome

complementation and judged by a phenotypic alginate overproduction screen. After
screening the entire 338 member cosmid library, one candidate complemented PAO568,
MTP93.
Localization of the MucD functional domains responsible for alginate
suppression and temperature sensitivity. To determine the functional domains of
MucD, mucD was amplified using primers with restriction enzyme tails common to a
shuttle vector, pUCP20. These primers included the forward primer at the beginning of
mucD and reverse primers ending at the ends of the protease domain of mucD and both
the ends of the PDZ1 and PDZ2 domains of mucD (Figure 23). The reverse primer used
for the end of PDZ2 was a primer homologous with the end of the mucD gene. After
amplification and subsequent restriction digestion of the products as well as the vector,
these were ligated and confirmed on validity and directionality of insert. Each of these
plasmids, the mucD protease, protease-PDZ1 domain pieces and full-length mucD were
transferred to a previously classified mucoid and temperature-sensitive PAO1 mucD
mutant, VE19, by tri-parental conjugation assisted by E. coli pRK2013 helper strain.
VE19 has a transposon insertion into the protease domain of the chromosomal mucD
resulting in transcriptional termination.

The resulting transconjugants led to full

complementation of the mucoid phenotype with both the full-length mucD as well as
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Figure 23.

The functional domains of MucD (1425 bp).

The arrows indicate the

positions and orientation of primers used. The location of the PstI restriction enzyme site
used in partial protease domain complementation is noted.
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the protease-PDZ1 domain length mucD (Figure 23). No complementation was seen
with only the protease domain of mucD. Additionally, when co-incubating these
complemented strains at 37 and 42°C, a temperature-sensitive effect was also noted.
Compared with the turbidity of growth at 37°C, both the full-length mucD as well as the
protease-PDZ1 domain length mucD displayed normal growth characteristics (Figure 24).
When complementing VE19 with only the mucD protease domain, a decrease in total
turbidity was seen. After this finding, a portion of the protease domain was deleted,
leaving only a partial mucD protease domain complementing VE19 (Figure 23). This
result led decreased growth at 42°C (Figure 24). These results show that only the first
PDZ domain is required for proper MucD activity regarding alginate regulation.
DISCUSSION
In this report, we have shown that point mutations rather than large genomic
rearrangements are associated with conversion to mucoid in P. aeruginosa PAO1. Four
unlinked loci have been identified to independently control the muc-23-specific
phenotypic switch. One of the loci has been delineated to a single gene named muiA
encoding a polypeptide, possibly located in the periplasm. The candidate genes for muiBD have been proposed due to the loss-of-function mutation rendered by transposon
mutagenesis in the respective cosmids. The control of mucoid mediated by the muiA-Dcontaining cosmids is via suppression of algD transcription, a key step in alginate
overproduction that depends on a putative signal transduction pathway. In addition, the
muc-23 allele can also be trans-complemented by mucA. Finally, we provided genetic
evidence that the muc-23 mutation is probably present in CF mucoid isolates. Although
these results describe that multiple loci within the PAO1 genome participate in the
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Figure 24. Temperature-sensitivity role of MucD functional domains.
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control of mucoid, they do not yield information regarding the molecular mechanism that
causes conversion to mucoid.
The genetic basis for conversion to mucoid in P. aeruginosa has been extensively
studied. There are two proposed molecular mechanisms underlying this conversion.
Genetic rearrangement is one proposed cause of in vivo conversion to mucoid in a rat
lung chronic infection model (139). On the other hand, it has been shown that mucoid
emerges with mucA mutations which result in inactivation of an alginate-specific antisigma factor, accompanied by overproduction of alginate (148). Thus, we wonder
whether both mechanisms may co-exist in alginate regulation. To study this possibility,
PAO1 was used, which is generally considered a prototroph with a non-mucoid
phenotype but is known to be able to overproduce alginate in the presence of an induced
mucA mutation (80). Furthermore, there are several available mucoid variants derived
from this strain carrying defined and undefined muc mutations. These muc variants were
originally created by Dr. J. Govan via growth selection of a PAO1 strain on nutrient agar
plates containing carbenicillin at a concentration of 1.5 times the MIC of the strain (39).
Since the genome of PAO1 is available, restriction endonuclease digestion of the PAO1
genome with SpeI and XbaI displays 37 and 99 large fragments, respectively (146). These
large genomic fragments can be resolved in a PFGE system. Major genomic
rearrangements within PAO1 and its muc variants are lacking (Figure 17). Although we
conclude that large genomic translocations appear to not be associated with mucoid
conversion in PAO1, we cannot rule out that minor rearrangements could be involved in
this conversion. The genetic rearrangements associated with the mucoid conversion could
be due to small insertion elements (122). The resolving power of the PFGE technique
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Figure 25. Schematic diagram of the entire genome of Pseudomonas aeruginosa strain
PAO1 (126). The scale on the outmost circle is in Mb. Outer and inner circles consist of
SpeI and XbaI digested fragments assembled in order, respectively.

Known SpeI

fragments are labeled in the outer circle with respective alphabetic letters. Locations of
P. aeruginosa genomic island-1 (PAGI-1) (68) along with algD and algUmucABCD loci
are noted.
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used only allows for the separation of large DNA fragments (50 – 450 kb fragments for
SpeI; 25 – 230 kb for XbaI, Figure 25). Furthermore, it is possible that large genomic
rearrangements or novel genetic materials in CF isolates can also be involved in this
conversion since the genomes of CF isolates are known to be extremely diversified and
often carry additional genetic materials absent from the PAO1 genome (48).
Nevertheless, in the case of PAO1, large genomic rearrangements seem to have a
minimal role in conversion to mucoid.
To provide an alternative to the existing functional genomics approaches,
including global gene expression microarray and proteomics, a whole-genome
complementation test based on a phenotypic selection was used (Figure 18). The
phenotype chosen is the mucoid colony morphology which can be maintained and easily
scored under in vitro conditions. To search for the muc-23 mutation, a comprehensive
complementation approach was pursued using the MTP library (55) for three reasons: i)
The library was derived from the original PAO strain; ii) It provides almost complete
coverage of the genome with a minimal number of overlapping clones; and iii) The
position of each clone relative to the PAO1 genome is known. Since the MTP library was
conveniently maintained in multiple 96-well microtitre plates, the test developed here
allows for small volume biparental conjugation between donor and recipient cells (150 μl
each) from each microtitre plate using a multi-channel pipette (Figure 18). In muc-23
cells, the sigma factor RpoN instead of AlgU has been proposed to drive the algD
transcription (Figure 3). Interestingly, even though PAO579 has the wild-type mucAB
genes (50), expression of a plasmid-borne copy of mucA without induction converts this
strain from mucoid to non-mucoid. Transcriptional regulation of algU is not fully
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understood because it is not clear how three out of its five promoters are regulated
(Figure 3). The genetic evidence presented here seems to argue that AlgU is somewhat
involved in the control of mucoid in muc-23 cells, even though rpoN participates in
alginate regulation. Indeed, inactivation of the rpoN gene in PAO579 rendered the strain
unable to overproduce alginate (50), consistent with the previous observation. On the
other hand, our results indicate that the wild-type mucA gene seems to have a wider
spectrum of mucoid-controlling activity. Therefore, MucA may become an anti-biofilm
therapeutic target. Initially, we identified 19 non-overlapping cosmid clones that had
activity related to mucoid suppression. However, after prolonged incubation, the majority
of these clones lost this activity. While the final four clones completely suppressed
mucoid, it is clear that there are other genomic loci that partially control this trait. Thus,
control of mucoid can be considered qualitative or quantitative depending on the loci
involved. However, it is clear that there are at least four unlinked loci that qualitatively
control conversion to non-mucoid in PAO579 and because the remaining 6.3% portion of
the PAO1 genome is not covered by the MTP library, this genome may carry additional
unidentified mucoid inhibitors which can not be determined with this method.
One of the major applications for complementation is its use in determining the
total number of different genes required to give rise to a particular phenotype. These
results indicate that there are four complementation groups capable of affecting mucoid
in the muc-23 background. Since MucA is an inner membrane protein with its C-terminus
facing the periplasm, it is possible that MuiA and MuiB, two periplasmic protein
candidates, may act upstream of MucA in the control of mucoid. Since mucoid control by
MuiA-D is operated via the suppression of algD transcription (Figure 22), these results
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appear to support a model that a putative signal transduction pathway exists across the
different cellular compartments in which multiple components are involved in the
repression of alginate synthesis. Particularly, it is interesting to note that expression of a
plasmid-borne mucA in PAO579 (mucA+ muc-23) without induction is sufficient to cause
conversion to non-mucoid (Figure 19). MuiA and B may have a role in relaying
environmental signals to directly to MucA or via MucB. In addition, there is genetic
evidence suggesting the linkage of auxotrophy and alginate overproduction. Among the
cosmids listed in Table 9, MTP307 carrying muiD is close to where the algR, algC, and
algB alginate-regulation loci are located on the PAO1 chromosome. Although muiD does
not have a mutation, it is possible that muc mutations may be located in the nearby
region. Furthermore, it is not clear whether there is more than one mutation in the muc-23
cells. Based on the fact that no mutations have been found in the coding regions of muiA
and D, there could be a difference in expression levels of these genes between PAO1 and
PAO579. Alternatively, the muc-23 allele may regulate the expression of muiA-D. If the
latter is true, the complementation pattern mediated by muiA-D-containing cosmids may
result from an epigenetic effect. Another example is that the muc-23 allele could be
dominant over the cosmids. This could explain why the muc-23 allele does not reside on
any of the four complementing cosmids. While MuiA and B are periplasmic protein
candidates, MuiC and D participate in the biosynthesis of lipid A and histidine,
respectively. So far, AlgC (PA5322), which encodes phosphomannomutase, is the only
enzyme with dual functions required for the biosynthesis of alginate and the LPS B-band
(41, 142). The current study offers one more candidate that links to the LPS biosynthetic
pathway but at the level of lipid A. Therefore, overproduction of alginate may affect the
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lipid A composition. In fact, it is known that CF isolates express a modified lipid A
portion of LPS (37). Therefore, these results further confirm that alginate regulation may
be connected to the pathways of amino acid and LPS biosynthesis.
Mucoid biofilms belong to one of the chronic infection phenotypes in the
pathogenesis of Pseudomonas lung infections in CF (146). CF isolates are often
auxotrophic mutants and are incapable of synthesizing methionine, leucine, arginine
and/or ornithine (6). Overproduction of alginate in CF isolates is associated with
reduction of P. aeruginosa virulence (117). Since CF isolates often display a mutator
phenotype (93), the muc-23 allele may be present in CF isolates. Expression of muiA-D in
muc-23 cells leads to phenotypic conversion to non-mucoid. The complementation
pattern appears to be specifically associated with the muc-23 allele because
complementation with these four cosmids in the mucA22 background has no effect on
alginate production. While it is known that mucA can complement the mucoid phenotype
in CF isolates, the four cosmids identified in this study were also capable of
independently suppressing a CF isolate with a known mucA22 allele. Therefore, it is
likely that the muc-23 allele exists in CF mucoid isolates, representing a mechanism that
is not well understood.
In reference to PAO568, the complementing cosmid (MTP93) consists of 20
ORFs, all of which have not been functionally classified and are not associated with any
currently known alginate regulating genes. This cosmid is able to exert its effect on the
mucA2 mucoid phenotype and thereby contains some factor that is potentially regulating
through a specific interaction or even through global regulation by way of algD
transcription.
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In conclusion, conversion to mucoid is associated with point mutations. There are
at least four unlinked loci in the P. aeruginosa PAO1 genome that are involved in the
control of mucoid (Figure 19). Each of these loci encoding a novel mucoid inhibitor is
able to exert its effect on muc-23-specific phenotypic conversion in a putative signal
transduction pathway leading to the suppression of algD transcription. Alginate
regulation may be controlled via muiA-D-dependent and/or -independent pathways.
In regards to MucD, even though both PDZ domains probably assemble in barrellike structure inside which target proteins are fed for proteolysis, having only one PDZ
domain may still play a role in target recognition involving protease function. However,
the absence of both PDZ domains still does not allow the protease domain of MucD to
even minimally affect those targets involved in the regulation of alginate. It is possible
that the targets for MucD degradation are in excess of the activity of the protease domain
alone without a PDZ domain with which to scavenge the proteins. Also, the temperature
sensitivity seems to have no bearing on the presence of the second PDZ domain. After
deletion of the first PDZ domain, there is reduced overnight growth at an elevated
temperature. This first PDZ domain, while necessary for alginate regulation, is only
partially responsible for MucD functionality at 42°C. It is possible that this PDZ domain
aids in the stability of the remaining portion of MucD and continues to allow proteolytic
activity. The entire protease domain of MucD is required, however, for growth at 42°C.
This effect is seen in VE19, which has no functional protease domain as well. Taken
together, while the binding domains of MucD are important in scavenging targets for
degredation leading to control of alginate production, the protease function is necessary
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for growth at elevated temperatures and also for alginate regulation in concert with at
least one PDZ domain.
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CHAPTER 5. IDENTIFICATION AND ANALYSIS OF BIOFILM
REGULATORS IN Pseudomonas aeruginosa
This chapter focuses on the phenotypic representation of a laboratory-created P.
aeruginosa SCV and its similarities to SCVs found within the CF lung. In this study, the
growth characteristics and biofilm formation of the laboratory SCV were found to be
similar to that of CF lung-isolated SCVs.
ABSTRACT
Biofilm formation of Pseudomonas aeruginosa is of clinical importance in CF.
This phenotype allows the bacteria to evade host defenses and antimicrobial treatment.
Periodically, CF sputa can yield variants of P. aeruginosa known as small colony
variants (SCVs). This notable phenotype has been shown to have an increase biofilm
forming-ability and a reduced planktonic growth rate.

To study this phenotype

effectively, however, a controlled strain was needed. In the laboratory, an SCV was
created from PAO1, the standard strain of P. aeruginosa, by depriving a 3 year-old
culture of nutrients.

Further analysis of this isolate displayed similar phenotypic

characteristics of those SCVs isolated from the infected CF lung. Through this, a more
effective study of SCVs can take place by creating laboratory SCV models from known
genetic backgrounds, such as PAO1.
INTRODUCTION
Pseudomonas sp. are ubiquitous in nature and able to adapt to changing
environmental conditions. When considering the CF lung, the major phenotype in P.
aeruginsoa is the mucoid phenotype. The genetic basis for these variants is very well
established as point mutations in structural or regulatory genes (11, 76, 78). Aside from
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this clinically important mucoid phenotype, it has been shown that dwarf colonies or
small colony variants (SCV) can be isolated from the chronically infected CF lung. The
emergence of this phenotype has been shown to correlate with poor lung function
parameters and poor response to inhaled antimicrobial therapy (45).

Small colony

variants of various bacteria have been implicated in persistent and recurrent infections,
such as endocarditis, pneumonia, and osteomyleitis with Staphylococcus aureus.
However, once immobilized from the site of infection, many SCVs are able to revert back
to their original phenotype. Generally, SCVs grow slower, have increased antibiotic
resistance and form more effective biofilms. This phenotype seems to have a selective
advantage in late stationary phase liquid cultures (45). Thus, it is thought that limited
nutrient conditions and increased oxidative stress might be factors favoring growth of
SCVs in the CF lung. This study was performed to determine if a laboratory-created
SCV is phenotypically representative of SCVs found within the CF lung.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strain used in this study was
PAO1, the standard and sequenced strain of P. aeruginosa, and originated from the
PGSC. P. aeruginosa was grown on Pseudomonas Isolation Agar (PIA) or in Lennox
broth (LB). All incubations were carried out at 37°C.
Biofilm assay. The assay for biofilm formation was adapted from the procedure as
previously described (91). Briefly, P. aeruginosa overnight culture was diluted 1:100 in
fresh LB medium, dispensed (125 μl) to wells of a 96-well polyvinyl chloride (PVC)
microtitre plate and grown for 15 h at 37°C with no aeration. Wells were stained with 100
μl 0.5 % crystal violet (CV) for 30 min at room temperature. Stain was discarded; plate
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was rinsed 3-5 times in standing water and allowed to dry. Stained biofilm was
solubilized with 200 μl 95% ethanol for 10 min and read at optical density at 570 nm
(O.D.570). Analysis for individual strains included 24 independent samples.
Determination of planktonic growth rate. For planktonic growth rate, an overnight 2
ml culture of sample was used to inoculate 200 ml LB. The sample was shaken and
O.D.570 readings were taken every 30 min for a total time of 9 h.
RESULTS
Laboratory generation of a PAO1-derived SCV. To study this phenotype, a
growth culture of the standard strain PAO1 was inoculated in 10 ml LB in a 50 ml
conical centrifuge tube in a shaking 37°C incubator. This culture was allowed to grow
for a total of 3 years with no replacement of media and no intervention except to remove
samples. Isolates were removed at inoculation, 1 year and 3 years post-inoculation and
isolated on PIA plates. The resulting growths on the original and 1 year samples were
phenotypically similar to PAO1 on PIA. The 3 year growth however, possessed two
different phenotypes: the typical PAO1 phenotype with a large round colony morphology
and the SCV phenotype with an small undulate colony morphology.
The growth rate of the PAO1-derived SCV mimics that of CF SCVs. Once
this phenotype was isolated, the growth characteristics were determined by growth rate,
compared with the original inoculum of PAO1 and the PAO1 1 year culture. Growth rate
was measured using a 1:100 dilution of overnight culture in 500ml LB shaken at 37°C.
Samples were taken at 30 min intervals for 9 h and measured for optical density at
O.D.600. The resulting curves showed not only a delayed lag phase but reduced log phase
growth and lower stationary phase bacterial counts when compared to the other two
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strains (Figure 26). Therefore the planktonic growth rate for the SCV was visibly lower
than the normally phenotypic original and 1 year isolates.
The biofilm forming ability of the PAO1-derived SCV is similar to that of CF
SCVs. Next, since SCVs have been shown to have enhanced biofilm formation ability,
this parameter was measured for all 3 strains. Using the 96-well biofilm assay, 24 wells
were measured per sample after 15 h of growth. The SCV mutant produced more than
double the amount of biofilm than the phenotypically normal strains (Figure 27).
DISCUSSION
Both the growth rate and biofilm formation results are in agreement with previous
studies (31, 35). Even though this SCV isolate was not isolated directly from a CF
patient, it still follows typical SCV phenotypic properties. This is also an example of in
vitro creation of SCV mutants. Because SCVs are thought to develop in low-nutrient
conditions, it was not unexpected to find these mutants within our inoculum. Because
our initial inoculated culture had been purposefully neglected for multiple years, nutrients
would be very limited. From 3 months post-inoculation, the culture assumed a nonturbid, clear appearance, signifying the lack of bacterial propagation. From this point
forward, there would have been high amounts of waste products present within the
media. Perhaps further nutrients were provided by not only the occasional introduction
of room air when taking samples, but from the remains of dead bacteria within the
container.

This abnormal environment has allowed for the emergence of the SCV

phenotype, which happens naturally within the environmental stresses of the CF lung.
Perhaps, through future studies, SCVs for other organisms could be generated in this
fashion and studied in vitro without any directed genetic modification.
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Figure 26. Planktonic growth curves of PAO1, PAO1 1 Year and PAO1 SCV strains.
PAO1 – blue diamond; PAO1 1 Year – pink square; PAO1 SCV – green circle. Samples
were analyzed every 0.5 h.
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Figure 27. Biofilm assay of PAO1, PAO1 1 Year and PAO1 SCV strains. Error bars –
standard deviation; asterisk designates statistical significance (P <0.001)
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CHAPTER 6. ROLE OF ALGINATE IN VIVO
This study looks to associate the production of alginate with an in vivo phenotypic
response. Using two pairs of mucoid and non-mucoid isogenic strains of Pseudomonas
aeruginosa, control and susceptible mice were exposed to aerosols of these sets of strain
and analyzed for lung colonization, mortality and virulence response.
ABSTRACT
Alginate is an exopolysaccharide that plays an important role in supporting
growth of Pseudomonas aeruginosa in CF lungs. While alginate has been considered a
structural component in the formation of biofilms, it has also been thought to contribute
to reduced virulence in the CF host. In this study, the role of alginate in a susceptible
mouse lung was tested using two sets of mucoid and non-mucoid isogenic mutants. With
the PAO1 standard strain, the mucoid mutant PAO1 mucB- showed similar colonization
but increased mortality in a susceptible mouse model when compared to the non-mucoid
PAO1 algD-. The clinical mucoid isolate FRD1 showed increased lung colonization, but
decreased mortality, decreased immune response and decreased virulence response when
compared to the non-mucoid FRD2, a mutant of FRD1. These data suggest the PAO1
isogenic strains have not adapted to a clinical CF situation and alginate has less of a
correlation. However, the FRD isogenic strains originated from the CF lung and the
presence of alginate result in decreased response by a susceptible mouse model. This
shows the role of alginate in lung colonization by CF strains of P. aeruginosa.
INTRODUCTION
Previous studies have indicated that the conversion of P. aeruginosa from the
non-mucoid to mucoid phenotype occurs mainly in the CF lung (43). This conversion is
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essential to the survival of the bacteria, in that the alginate overproduction is an important
factor used to evade host defenses and antimicrobial therapy in the CF lung. Also, the
assembly of mature biofilms is directly dependent on alginate as a structural matrix.
When viewed from the bacterial perspective, co-habitation with the host is a preferred
scenario. It is hypothesized that the colonizing strain of P. aeruginosa in a CF lung is
attenuated in virulence over time due. This is because the strain wants to co-exist with
the host and this decrease in virulence is thought to happen through the production of
alginate. Also, studies have shown that this colonizing bacterium is confined to the lung
throughout the life of the CF patient and never goes systemic. Therefore, it was of
interest whether the colonization of the lung and conversion to the mucoid phenotype led
to virulence attenuation. To address this, a study was performed to determine the effect
of mucoid conversion on virulence in a susceptible mouse model. Using a BAILI mouse
model susceptible to lung infection, the mice would be exposed to an aerosol of CF and
non-CF isogenic pairs of P. aeruginosa strains of the mucoid and non-mucoid phenotype.
In this study, the susceptible mouse model used was DBA/2 and the control mouse was
C57BL/6.

DBA/2 mice have an increased inflammatory response to bacterial lung

infection (120). Because of this response, more neutrophils are recruited to the site of
infection, resulting in increased lung damage from these immune cells. The CF strains
used in this study were FRD1, a clinical mucoid CF isolate with a point mutation in
mucA, and FRD2, a non-mucoid mutant of FRD1 with a mutation of unknown origin.
The non-CF strains for this study were a mucoid mutant of PAO1 with a transposon
insertion into mucB, a non-mucoid mutant of PAO1 with a transposon insertion into algD
and the standard non-mucoid PAO1 as an internal control. An algD mutant of PAO1 was
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used to determine if the minimal amount of alginate from the standard PAO1 had any
effect throughout the study.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacterial strains used in this study are as
follows: Pseudomonas aeruginosa strains PAO1 algD- (non-mucoid; inactivation of
algD), PAO1 mucB- (mucoid; inactivation of mucB), FRD1 (mucoid; clinical CF isolate)
and FRD2 (non-mucoid; FRD1 with unknown mutation resulting in loss of mucoid
phenotype). P. aeruginosa was grown on Pseudomonas Isolation Agar (PIA) or in
Lennox broth (LB). All incubations were carried out at 37°C.
P. aeruginosa aerosol infection mouse model. P. aeruginosa overnight culture (1 ml)
was used to inoculate 100 ml LB broth and was grown for 14-16 h with aeration at 37°C.
The cells were pelleted and resuspended in 10 ml P-PBS (1% proteose peptone-PBS).
The cell suspension (5 ml) was dispensed into the nebulizer-Venturi unit of the Inhalation
Exposure System (Glas-Col, Terre Haute, IN) and aerosolized for 30 min (compressed air
control = 20; vacuum control = 50), cloud decayed for 25 min, and UV decontaminated
for 5 min. A total of 15 mice were exposed for each strain with 5 C57BL/6 mice
terminated at t = 0 and 10 mice (5 C57BL/6 and 5 DBA/2) terminated at t = 6 h. Mice
were sacrificed by carbon dioxide. At t = 0, no DBA/2 mice were used because previous
studies have shown that similar bacterial levels exist after initial exposure (120). The
right lung was removed, homogenized in 1 ml P-PBS and plated via serial dilution on LB
agar. The left lung was filled with 2% paraformaldehyde sectioned and stained with H/E
(hematoxylin and eosin) stain for histopathology studies. An additional 5-11 C57BL/6
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and 15-16 DBA/2 mice were viewed over the course of 192 h for lung infection-related
mortality.
Mouse cytokine array. Lung homogenate was analyzed for mouse cytokines using a
Mouse Cytokine Array 3.1 (RayBiotech) per the manufacturers instructions. Resulting
data was normalized to the negative control and compared as a differential folddifference of expression versus another strain.
RESULTS
Lung colonization after aerosol exposure to P. aeruginosa mucoid and nonmucoid isogenic strains.

After aerosol exposure, viable lung counts of surviving

bacteria were determined (Figure 28). Based on the colonization studies, while the
C57BL/6 t = 0 h lung counts are conserved throughout the isogenic strains involved, by
t = 6 h these control mice show a bacterial clearance of 1 to 2 logs of growth (Figure 28).
The increased clearance of FRD2 in control mice could be attributed to the non-mucoid
phenotype and the related ease of host immune system clearance. In the attenuated
PAO1 background, this phenotypic difference is not manifested the same way in lung
clearance. However, when comparing the t = 6 h levels in DBA/2 with the t = 6 h levels
in C57BL/6, all strains show increased colonization.

This shows the colonization

potential of the DBA/2 lung and the susceptibility to lung infection under aerosol
delivery. The increased bacterial numbers in FRD1 suggests some active growth through
the 6 h period of incubation. The mouse colonization data for FRD1 and FRD2 show a
statistically significant difference in bacterial load at t = 6 in DBA/2 mice when
compared to t = 0 in C57BL/6, signifying a difference in these isogenic strains.
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Figure 28. Box plot of viable P. aeruginosa lung counts after aerosol exposure to control
and susceptible mice. The box plot shows the median (black bar) and 75/25 percentiles
(top and bottom of box, respectively).
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Aerosol exposure of strains results in two differing survival patterns in
susceptible mice. When following the remaining mice post-colonization for mortality,
an interesting trend emerged. While the non-mucoid PAO1 algD- strain resulted in
survival of 11 of 16 DBA/2 mice, the mucoid isogenic partner, PAO1 mucB- had an
increased level of mortality, 6 of 15 (Figure 29). This result suggests increased alginate
production led to increased mortality in DBA/2, while it is thought that the mucoid
phenotype suppresses virulence. PAO1 is the standard strain of P. aeruginosa and has
been completely sequenced. This strain originated as a burn patient isolate and has since
been passed through the laboratory for many years. It appears as if PAO1 still possesses
an inherent virulence property that is not dependent on the alginate state. While the
differences in the mortality data can be seen in Figure 29, the convergence of the data at
48 h results in the data not being statistically significant. Also, as noted on this figure, all
of the C57BL/6 mice remained alive throughout the study. A different situation is found
in Figure 30. In this case, the non-mucoid FRD2 resulted in decreased survival of
DBA/2, 5 of 16, and the mucoid FRD1 led to increased survival, 14 of 15. Also, while
mucoid FRD1 had significantly increased colonization at t = 6 h in DBA/2 compared
with non-mucoid FRD2, it resulted in less mortality.
Lung response to aerosol exposure of mucoid and non-mucoid isogenic
strains. Histopathology sections of aerosol exposed mice were prepared to determine the
effect of alginate. For the PAO1 isogenic mutants, no notable differences were seen at
histopathology (data not shown). However, for the FRD1 and FRD2 strains, differences
were noted with the DBA/2 mice (Figures 31, 32). Multiple focal neutrophil groupings
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Figure 29. Survival plot of mouse strains subjected to aerosol exposure of P. aeruginosa
PAO1 isogenic mucoid and nonmucoid strains.
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Figure 30. Survival plot of mouse strains subjected to aerosol exposure of P. aeruginosa
CF isolate FRD1 and its isogenic, nonmucoid mutant FRD2.
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Figure 31. Lung sections of C57BL/6 mice exposed to mucoid P. aeruginosa CF isolate
FRD1 and its isogenic, nonmucoid mutant FRD2. A) 40X and B) 600X magnifications
of a lung lobe and alveolar space, respectively, 6 h after FRD1 aerosol exposure. C) 40X
and D) 600X magnifications of a lung lobe and alveolar space, respectively, 6 h after
FRD2 aerosol exposure. Samples were H/E stained and viewed by light microscopy.
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Figure 32. Lung sections of DBA/2 mice exposed to mucoid P. aeruginosa CF isolate
FRD1 and its isogenic, nonmucoid mutant FRD2. A) 40X and B) 600X magnifications
of a lung lobe and alveolar space, respectively, 6 h after FRD1 aerosol exposure. C) 40X
and D) 600X magnifications of a lung lobe and alveolar space, respectively, 6 h after
FRD2 aerosol exposure.

Arrows denote the presence of neutrophil conglomerates

throughout the lobe for both samples. Samples were H/E stained and viewed by light
microscopy.
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(purple dots) were found with both FRD1 and FRD2 strains in DBA/2, but more were
found with FRD2.
Analysis of virulence response due to mucoid and non-mucoid isogenic
strains. Lung homogenate was also analyzed for 62 cytokines/proteins to determine if
alginate overproduction was related to the presence of any biomarkers. The results from
this analysis are listed in Table 10.
DISCUSSION
It has been shown that production of alginate occurs within six hours of in vivo
inoculation (113). These findings support alginate overproduction leading to decreased
virulence with the FRD strains, the reverse situation compared to the PAO1 isogenic
strains. Again, in the case of the FRD strains, the DBA/2 data is statistically significant
and the C57BL/6 mice all survived.

While lung pathology showed no remarkable

findings of infection with the PAO1 isogenic strains (data not shown), the FRD isogenic
pair showed differences based on the alginate phenotype. The control C57BL/6 mice
histopathology lung sections for FRD1 and FRD2 infections were unremarkable. With
the DBA/2 lung, however, an interesting finding was seen. Throughout the lung samples,
multiple focal neutrophil conglomerates are clearly visible. The presence of these foci is
synonymous with the phenotype of DBA/2 having increased neutrophil recruitment.
Although these foci are found in both FRD1 and FRD2, more of these foci were located
in the FRD2 sample. This finding is synonymous with increased mortality in the FRD2
sample. The absence of alginate in FRD2 could have also led to an increased immune
response from the host due to the increased virulence. This finding is echoed in the
previous data, where decreased bacterial load of FRD2 at t = 6 h, when compared to
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Table 10. Cytokine analysis of mouse lung homogenate after P. aeruginosa exposure

*Left column: cytokine/protein assayed; top row designates the two bacterial strains
compared against each other in related activity; bottom row designates the mouse within
which the two strains were tested; values represent the fold-amount of up-regulation
between the bacterial strains; colored boxes show the range of up-regulation of one strain
versus another; white boxes show no up-regulation; values are corrected to negative
control
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FRD1, led to increased mortality over 192 h. Possibly, the alginate overproduction by
the FRD1 strain is hindering or even suppressing the host response. Whatever the
mechanism, the alginate overproduction by FRD1 leads to increased t = 6 h colonization
in DBA/2, but decreased mortality and less focal neutrophil conglomerates when
compared with its non-mucoid counterpart, FRD2.
With the cytokine data, no clear determination can be made between alginate
production and specific cytokine/protein levels. When comparing this data (Table 10)
with the mortality data (Figures 29, 30), increased mortality of DBA/2 was synonymous
with increased up-regulation of multiple cytokines/proteins when compared to the less
virulent isogenic strain of the pair. PAO1 mucB- and FRD2, while differing in alginate
phenotype, both elicit a heightened immune response. In this study, pairs of isogenic
strains of P. aeruginosa were tested for their colonization potential, ability to cause death,
and ability to elicit a cytokine response in the lung in a susceptible mouse model. While
the laboratory strain PAO1 derivatives showed inverse effects to those of the FRD
strains, both were able to colonize the susceptible mouse lung. By merely modifying the
alginate production, these strains showed a similar ability to initially colonize with a
variance in mortality and immune response in a susceptible lung model.
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CHAPTER 7. CREATION OF TOOLS FOR IDENTIFICATION AND
ANALYSIS OF NOVEL ALGINATE REGULATORS RELATED TO BIOFILM
FORMATION IN Pseudomonas aeruginosa
Creation of a new transposon delivery plasmid, pED1
In order to utilize the large amount of information available within the recently
sequenced PAO1 genome, certain techniques were devised to locate novel biofilm
formation inhibitors. One approach involves the use of a mariner-based transposon
system (1). By using the mariner transposon pFAC, random transposon mutagenesis can
be imparted on the genome of PAO1, eliciting many different physiological effects (138).
For this study, the focus was on the conversion of the non-mucoid PAO1 to the alginate
overproduction phenotype. Biparental conjugation allowed the transfer of pFAC from
the donor E. coli strain into the recipient PAO1 followed by selection of mucoid
transconjugants on gentamycin, the marker for the pFAC transposon. Use of this vector
proved valuable in the work of others in the laboratory. However, a tool for consistent
and robust use in P. aeruginosa was sought. The success of pFAC is limited by the
ability of the transposon-accepting host strain to be resistant to the level of gentamycin
needed to select for the marker. In certain instances, strains of P. aeruginosa are highly
resistant to gentamycin, making this situation an issue. For that reason, pFAC was
chosen for genetic modification. To assemble a new transposon, the pFAC backbone was
used and the gentamycin cassette was replaced with a tetracycline marker. By restriction
digestion, the backbone was isolated. The tetracycline cassette was amplified by PCR
from pVDZ’2 (29) with restriction enzyme tails, common to the pFAC backbone. These
two were then ligated together and confirmed by sequencing. The resulting transposon
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plasmid was named pED1. The efficiency of transposon insertion was determined by
screening multiple tetracycline-resistant insertion clones against selection for
carbenicillin, which is the marker on the transposon plasmid backbone. This determines
the ability of the transposon to insert into target DNA by double-crossover without
integrating the backbone of pED1 by single-crossover. After screening ~500 clones,
pED1 proved to be ~100% effective in transposon delivery. Transposon mutagenesis
was tested using pED1 on PAO1 and screened for non-mucoid to mucoid conversion.
Using this procedure, known alginate-regulating genes algB and mucB were located.
Transposon systems such as this can also be used for multiple different phenotypic
screens, including motility, twitching, pigment, pathogenicity and biofilm formation, to
name a few. Overall, the creation of this effective and fully functional transposon marker
will allow for further functional analysis of many different strains of P. aeruginosa.
Creation of a new knockout vector, pED6
A key tool in the process of novel gene identification in P. aeruginosa is an
effective method in performing a gene knockout. In order to convincingly prove the
functionality of a gene of interest, the gene should be functionally inactivated. Many
different methods can be used to perform such a gene inactivation. A method used in the
current studies is based on a knockout system, pEX100T (115). This system is based on
a Pseudomonas suicide vector, in that it is able to fully replicate in E. coli but not within
Pseudomonas. This technique allows for a gene exchange from the pEX100T-based
system to the Pseudomonas target genome, and not a co-existence of plasmid within the
cell. This system also contains a lacZ marker used for a blue and white screen to confirm
proper insertions into a restriction site.

Also included is a sacB gene coding for
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levansucrase, of which its action in cell death is not entirely clear. However, it is thought
that in the presence of sucrose, levansucrase yields an accumulation of levans, or high
molecular-weight fructose polymers, in the periplasm that might be toxic.

This

characteristic prevents the knockout system from integrating within the target genome by
single-crossover. The resulting single-crossover insertion will lead to the demise of the
cell in the presence of sucrose. One last marker within this system is an antibiotic
resistance marker for ampicillin. pEX100T is a powerful vector and allows for site
directed gene exchange with the target genome. However, pEX100T is not suitable for
Pseudomonas. This plasmid allows the integration of a genetic sequence of interest at a
SmaI restriction site. However, SmaI is a blunt-end cutter, resulting in no base pair
overhangs for common overhang ligation of target products. For this reason, small linker
nucleotide overhangs for the restriction enzyme XbaI were ligated to the blunt-ended
SmaI sites. This restriction site was selected because it occurs very infrequently in the P.
aeruginosa genome (99 times), thereby lessening the chance of it occurring within a gene
of interest. The resulting plasmid is pEX100T with an XbaI site where the previous SmaI
site existed. This modified and resulting plasmid was named pED6 (Figure 33). To
perform a typical gene knockout in P. aeruginosa using pED6, first a gene of interest is
amplified by PCR using primers with embedded XbaI-tails. Again, it is essential that the
gene amplified have no XbaI restriction site. Once this product is amplified, it is digested
with XbaI to expose the single-stranded overhangs for further ligation. Also, pED6 is
digested with XbaI for the same reason. The two resulting products are ligated together
and screened by blue and white colony color to select for valid insertion clones. Once a
valid clone has been located and confirmed by PCR via the M13 priming sequences
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Figure 33. A pED6 knockout system developed for specific gene inactivation on the
Pseudomonas genome. A gene is selected for knockout is PCR amplified using XbaItailed primers. A Pseudomonas suicide vector as well as the amplified gene is digested
with XbaI, ligated and subjected to random transposon mutagenesis. This mutant library
is mated with PAO1 and selected on PIA with tetracycline and 10% sucrose. The gene
knockout can be confirmed by phenotypic screen, PCR, Southern analysis and
complementation with the wild-type. Here, the inactivation of the target gene results in
the mucoid phenotype.
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flanking the XbaI site in the pED6 backbone, random transposon mutagenesis is
performed using a common tetracycline transposon insertion kit. This results in a library
of transposon insertion clones which are then transformed into E. coli. The transposon
mostly targets the pED6 backbone but will sometimes insert within the gene of interest.
The latter are the clones of significant interest. The resulting library will be mated by
triparental conjugation, allowing the transfer of plasmids from the donor E. coli strains
into the recipient strain (in this case, P. aeruginosa PAO1) with the hyperpiliated E. coli
strain pRK2013, to assist in the conjugation. The resulting conjugation will be selected
by growth on PIA (Pseudomonas Isolation Agar), with supplemented sucrose (10% w/v)
and tetracycline (300 μg/ml). The resulting conjugant growth will first be PAO1 only,
due to the PIA selecting out all the E. coli. Second, the sucrose will select against any
conjugants with a single-crossover of pED6, resulting in an integration of the sucrase
gene and therefore, cell death. Third, the tetracycline will select out any of these doublecrossover conjugants that have the tetracycline cassette inserted into the gene of interest
that will now replace the chromosomal copy by homologous recombination.

To

summarize, using the pED6 system with specific gene knockout ability, the capability
exists to specifically inactivate any non-essential gene of interest by double-crossover of
a mutant replacement gene copy. The action of pED6 has proved to be rapid and
powerful through these studies. Directed knockouts of P. aeruginosa genes such as algB,
kinB, mucA, mucB, mucD, and rpoN have been performed using pED6, furthering many
of the studies in this work.

127

Creation of transposon vectors pED2 and pED3, allowing integration of naked DNA
through the λ Red system
An additional technique that can be used to inactivate specific genes of interest
within the P. aeruginosa genome involves a very common method originally perfected
for use with E. coli. This approach involves the use of a phage integration system called
λ Red. In this system, Red stands for Recombination deficient. When utilizing λ Red,
naked DNA can be recombined with the host genome (84). In this sense, utilizing this
system in P. aeruginosa would improve the efficacy of gene knockouts. In order to
create a gene knockout using the λ Red system, a common approach is to integrate an
antibiotic resistance marker within the gene-directed naked double-stranded DNA. This
approach involves PCR amplification of an antibiotic resistance marker from any target
DNA of interest, keeping in mind that the primers used for such an amplification be
complementary to not only the resistance marker but also homologous to the genetic
knockout target on the host genome.

Varying primer lengths for knockout target

homology will depend on the specificity required for the recombination at the host
genome. Alongside this naked DNA, the λ Red system genes are also required. The λ
Red system comprises 3 genes.

The first gene, exo, yields a product that is a λ

endonuclease, which progressively degrades the 5’-ended strand of double-stranded
DNA, generating 3’-ended overhangs (70). The exonuclease is a ring-shaped trimer with
a passage through the center that can accommodate double-stranded DNA at one end but
only single-stranded DNA at the other (62). The product of the next gene, bet, binds to
single-stranded DNA, promotes renaturation of complementary strands, and is capable of
mediating strand annealing and exchange reactions in vitro (66). Finally, the gam gene
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product, which when formed as a dimer binds to the host RecBCD protein and inhibits all
of its known activities. RecBCD is the resident recombination system in normal cells
(83).

For λ Red to work effectively, it must deactivate the RecBCD system.

To

introduce these genes within a host P. aeruginosa strain, two approaches were taken.
One method involves placing the λ Red system genes on a shuttle vector, a plasmid that
can actively replicate and be functional in two organisms.

In this case, these two

organisms are E. coli and P. aeruginosa. To do this, the λ Red system genes were
removed from their parent plasmid pKD46 (58) by restriction digestion and ligated into
the shuttle vector pVDZ’2, digested with the same restriction enzymes. The resulting
plasmid, named pED2, expresses the λ Red system genes within the P. aeruginosa
genome. Another approach involves integrating a chromosomal copy of the λ Red
system genes on the target chromosome. This is done by way of the plasmid mini-CTX1
(115). Using the same techniques as with pED2, the λ Red system genes were removed
from their parent plasmid and integrated into mini-CTX1 by restriction digestion and
subsequent ligation. This plasmid is named pED3. By way of a recombination event,
these genes are transferred from the mini-CTX1 backbone to the attB site, thereby
integrating within the host genome. It is this chromosomal copy of the λ Red system
genes that will act on naked DNA transformed into the host cells as previously described.
It is important to note that when moving the λ Red system genes, the inducible arabinose
promoter, ParaB, must be present before the λ Red operon. Also, the araC, encoding a
repressor for the ParaB, must also be included. When the λ Red system genes along with
the ParaB promoter and araC repressor are mobilized to create these new vectors, pED2
and pED3, then induction of the λ Red system to promote recombination of naked DNA
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is driven by the addition of arabinose.

The arabinose will bind AraC and allow

transcription from the ParaB promoter of the λ Red genes. These tools can be useful for
B

specific and rapid inactivation of genes within the P. aeruginosa genome.
Construction of algU promoter fusions with GFP and lacZ
The formation of mature biofilm structures in P. aeruginosa has been extensively
studied. However, many details have yet to be discerned regarding specific gene activity
during the formation of biofilms. For this purpose, two tools were constructed to aid in
the elucidation of gene regulation in biofilm formation. The first involves measuring, in
vivo, the activity of key regulators of the alginate production pathway. As stated before,
the formation of a biofilm requires a matrix within which it will progress towards a
mature biofilm. In P. aeruginosa, the master positive regulator of alginate synthesis is
AlgU. Utilizing genomic information and previous work, is has been discerned that algU
possesses five promoters that hypothetically drive expression of differing portions of the
algUmucABCD operon (Figure 3). Because research into the gene expression during the
initial formation is important in determining the exact stepwise fashion of biofilm
construction, it is necessary to have a tool to detect gene regulation within these
structures. To construct such a tool, the thought was to measure algU promoter activity
by creating GFP and lacZ fusions. To create the GFP fusions, algU promoters 1, 1-2, 13, 1-4 and 1-5 were PCR amplified with restriction enzyme primer tails synonymous with
the multiple cloning site of mini-CTX1-GFP (Figure 34; (52)). After amplification, both
the PCR products and the vector were digested accordingly and ligated. After ligation,
directional confirmation and checking the coding frame, the mini-CTX1 P1-GFP,
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Figure 34. Genetic map of mini-CTX1-GFP integration plasmid. GFP – encodes green
fluorescent protein; tet – responsible for tetracycline resistance; int – responsible for
integration into genomic DNA.
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mini-CTX1 P2-GFP, mini-CTX1 P3-GFP, mini-CTX1 P4-GFP, mini-CTX1 P5-GFP
plasmids were created. The inclusion of the downstream promoters along with promoters
2, 3, 4 and 5 were made to detect the additive effect of each successive promoter. It was
thought that fusing each promoter alone with the GFP would result in a masked effect,
due to the known auto-regulation of algU through promoters 1 and 3. The ultimate
purpose for these constructs is to visualize with a light microscope and confocal
microscope, a biofilm undergoing different stages of development. These vectors have
been initially studied, but have not been methodically used in biofilm studies. With
regard to creating lacZ fusions with the various algU promoters, the same procedure was
followed in constructing the GFP fusions by using mini-CTX1-lacZ (Figure 35; (52)).
Also, for a specific study, the algU promoter 2 alone was fused with the lacZ reporter
according to previous methods. These constructs can be used to determine the specific
amount of activity driven by specific algU promoters in a biofilm through betagalactosidase assay of biofilm growth.

They can also be used to determine algU

promoter activity within the planktonic cell in determining the specifics of alginate
regulation through algU. The latter situation has yielded fruitful results in the second
manuscript enclosed. The creation of these tools to analyze gene regulation in the
formation of biofilms allows for key findings regarding algU-specific alginate regulation
to be reported, furthering current research on the stepwise assembly of P. aeruginosa
biofilms.
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Figure 35. Genetic map of mini-CTX1-lacZ integration plasmid. lacZ – responsible for
lacZ-related activity; tet – responsible for tetracycline resistance; int – responsible for
integration into genomic DNA.
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CHAPTER 8. GENERAL DISCUSSION
DISCUSSION
Understanding the formation of biofilms is critical in addressing the issue of P.
aeruginosa lung infections in CF. The six chapters of the dissertation presented here
addresses different aspects of biofilm formation and the characteristics of P. aeruginosa
in the lung environment. This discussion will review the findings of the six studies,
briefly compare the results and address future studies.
The first study (Ch. 2) addressed the hypothesis that genotypic and phenotypic
variations exist among different sources of P. aeruginosa and contribute to the
pathogenesis in CF. CF isolates, non-CF clinical isolates, environmental isolates and
laboratory strains of P. aeruginosa are all vastly different. In relation to initial biofilm
formation, all strains show different biofilm forming abilities with no correlation to initial
biofilm characteristics, such as motility, type-IV pili activity, alginate production. While
sensitivity to oxidative radicals and decreased clearance of mucoid cells from the mouse
lung supports the phenotypic relationship, other factors must be influencing the
development of biofilms. As witnessed with the enormous amount of genomic diversity
and additional genomic material possessed by clinical strains, the complexity of the
resulting phenotypes and virulence in CF patients is difficult to address. However,
through novel genetic techniques, such as subtractive hybridization coupled with RAPD
as well as further genomic mining into these clinical strains, more information can be
gathered regarding the formation of the clinically important biofilm phenotype. This
study was the first to show variability in biofilm formation in different isolates of P.
aeruginosa. Also, this work was the first to address that no direct relationship exists
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between individual biofilm characteristics. Finally, while previous studies have used
costly, shotgun sequencing techniques to identify novel genetic material, this work shows
the development of an inexpensive and effective procedure. This study reinforces the
diversity and disparity throughout P. aeruginosa genetically and phenotypically.
The second study (Ch. 3) focused on the hypothesis that unphosphorylation of
AlgB results in alginate up-regulation through algU.

This involves a novel two-

component signal transduction system involved in regulation of alginate production.
KinB, the sensor kinase, was shown to phosphorylate AlgB leading to suppression of
alginate production, a finding that disputed a previous study. Unphosphorylated AlgB
was also shown to interact with the algU promoter when positively regulating alginate.
This novel finding represents the first two-component system in Pseudomonas sp. that
has a dual-role in both type-IV pili synthesis and alginate production under
phosphorylation control. Due to these results, a new understanding will arise regarding
the effect of alginate regulators at the algU operon, leading to more effective control of
biofilm formation. This study is a clear example of the need for further elucidation of the
mechanisms regarding alginate production and biofilm formation.
The third study (Ch. 4) addressed the hypothesis that additional biofilm regulators
existed within the P. aeruginosa PAO1 genome. Through this, known and unknown
areas of the P. aeruginosa genome that regulate the formation of mucoid biofilms were
investigated. Previous works utilized costly microarray and indiscriminant 2D protein
gels to find new biofilm regulators. By utilizing isogenic mutants of the standard strain,
PAO1, novel regulators of alginate production were located and annotated. By way of
useful high-throughput genetic tools, such as the PAO1 MTP cosmid library, new biofilm
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regulators were located.

Also, with this whole-genome complementation approach,

spontaneous mutants in CF isolates leading to alginate overproduction can potentially be
described.

Also, further characterization of the functional domains of an alginate

inhibitor, MucD, can lead to the detailed mechanism of this important periplasmic
protease.

This work, including the identification of novel alginate genes and the

understanding of an identified gene, mucD, helps in the further development of
treatments towards key molecular targets involving alginate synthesis in P. aeruginosa
lung infections.
The fourth study (Ch. 5) described a phenotype whose importance is becoming
increasingly recognized in the field of P. aeruginosa biofilms. The small colony variant
(SCV) is clinically relevant in many device-associated clinical infections. Bacteria with
this phenotype are also isolated from the sputum of CF patients. While the significance
of this phenotype is unknown, previous studies have shown its preferred mode of growth
clinically is as a biofilm (32, 35). This study not only addresses the phenotypic effects of
SCVs and their proposed actions in the CF lung, but also identifies a mechanism for the
emergence of SCVs without the use of directed external genetic modification. The
availability of these mutants will allow more flexibility in determining their absolute
effect in CF lung pathogenesis.
The fifth study (Ch. 6) focused on the role of alginate in vivo. By using mucoid
and non-mucoid isogenic strains of P. aeruginosa, alginate-overproducing strains showed
a direct correlation with lung retention, evasion of the host response and decreased
virulence. Although a laboratory isogenic pair showed that alginate production enhanced
mortality in a susceptible mouse model, a CF isogenic pair followed the same trend as the
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other results, leading to reduced mortality. This approach suggests that in CF isolates,
the overproduction of alginate, leading to the formation of initial biofilms, suppressed the
immune response and led to more of a co-habitation with the host compared to the
laboratory strain, which had increased mortality with increased alginate. Testing for the
production of alginate in relation to initial biofilm formation in a mouse model is one of
the first steps in properly translating laboratory research on the regulation of biofilm
formation to treatments in the CF patient.
The sixth and last study (Ch. 7) addressed the continued need for novel genetic
tools to identify and confirm new biofilm regulators of alginate production.

The

evolution of clinical bacterial species towards anti-microbial resistance continues to
affect the afflicted patient. In addition, this bacterial evolution also continues the need
for new genetic tools in the scope of curing such a patient. In other words, once
antibiotic resistance arises in P. aeruginosa, another genetic weapon used to further
investigate the phenotypic mechanisms of this organism is taken away. To circumvent
this emergence, novel genetic tools must be created and utilized. One such example is
pFAC, a transposon mutagenesis vector used to randomly mutagenize the P. aeruginosa
genome to identify novel biofilm regulators. This vector, while mostly effective, is
resistant to gentamycin at 300 μg/ml, but some strains are also increasingly resistant. For
this reason, pFAC was converted from a gentamycin marker to that of tetracycline
(pED1) to supply another option in the further characterization of the alginate regulation
pathway. Also, in the process of identifying novel genes, gene knockouts must be
performed. By modifying a previous vector, pEX100T, better suited for use in these
studies, pED6 was created. This novel vector allows the process of gene knockouts in P.
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aeruginosa to be reduced from 4-6 weeks down to less than 1 week. This efficient and
essential technique will only increase the productivity of genetic inactivation and
functional determination. Also, a recombination system created for gene inactivation in
E. coli, λ Red, was assembled into Pseudomonas-compatible vectors for plasmid-borneand chromosomal copy-versions for use in gene replacement.

Through this, gene

knockouts may be performed with relative ease. Finally, determining the specific activity
of the alginate regulation pathway in specific situations requires special reporter systems.
When analyzing the intricate formations of biofilms, understanding internal gene
regulation may be of value. By fusing the promoter regions from the key alginate
regulator, AlgU, with a visual marker, GFP, this can sense the algU activity within a
biofilm and be visualized by microscopy. Also, when studying the algU activity under
specific genetic modifications, the intricacies of the specific interactions with algU under
experimental conditions can be highly reproducible.

Again, by fusing the algU

promoters to a lacZ marker, the specific activity of other known and unknown alginate
regulators can be determined. These studies are essential to the progression of genetic
elucidation of biofilm regulatory mechanisms in P. aeruginosa. While current genetic
tools are slowly becoming obsolete due to phenotypic evolution of P. aeruginosa, the
addition of novel tools will result in the continued studies regarding the biofilm
phenotype.
Many future studies can be followed up from this work and applied throughout
the realm of P. aeruginosa biofilm regulation.

First, due to the costs and loss of

resolution of different types of high-throughput genetic screens, novel mechanisms for
new gene identification need to be found. While these studies can perform many tasks at
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once, most of the measuring capacity of these systems is unable to determine low-level
expression changes, especially in regards to alginate regulation and the sigma cascade.
As seen in this study, the use of simple genetic techniques has revealed many findings
that would not necessarily be determined by a general snapshot of gene activity or protein
production.

Developing additional techniques in the light of random transposon

mutagenesis and low-copy cosmid complementation, as well as exploiting phenotypic
markers and genetic tools from studies involving different organisms will further
regulation studies by creating representative situations that are normally masked in highthroughput techniques.
Next, addressing the situation of genomic diversity in CF isolates is important.
As shown in this study and others, it appears as if PAO1 has the smallest genome when
compared to all clinical, environmental and laboratory isolates of P. aeruginosa. This
standard strain may not be representative of many of the physiological interactions in this
organism. As seen here, many genomic and pathogenicity islands have been identified in
P. aeruginosa, which encode genes that lead to increased virulence. Studies involved in
determining the origin of these novel genetic elements as well as the genetic makeup of
clinical CF isolates need to be done. While the cost of complete genome sequencing is
high, the benefits to the CF patient in reworking the current therapies to better suit the
individual, instead of the general condition, are higher. These studies will only shed
more light on the complexity of the CF infection and open new doors to potential targets
for treatment.
Finally, the development of a functional and representative CFTR-knockout
animal model is desperately needed in the realm of CF research. In this study, normal
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mice and susceptible mice were used to display the virulence of certain strains of P.
aeruginosa.

However, the current models do not simulate the human CF lung

susceptibility, and thus result in a roadblock for promising findings in controlling P.
aeruginosa infections. Potentially, by creating a hybrid mouse model combining the
current, non-functional CFTR-knockout mouse with various other susceptible mice will
yield a more feasible model than those that currently exist. With continued development
of the nutritional requirements and delivery to these fragile mouse models, a more
representative simulation of CF lung infection may allow for proper studies involving
colonization, alginate production, biofilm formation, host response and anti-microbial
therapies.
Taken together, the current work and future studies will continue to lead towards
a clearer understanding as to the molecular mechanisms underlying the relationship
between the susceptible CF lung and phenotypic manifestations of P. aeruginosa in CF.
Through this, a brighter future can be presented for those currently afflicted with CF and
their families.
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